Training module 1: Summary

Size: px
Start display at page:

Download "Training module 1: Summary"

Transcription

1 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 1: Summary Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

2 Mdule 1 Summary Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

3 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule 1 Summary This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

4 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule 1 Summary These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

5 Mdule 1 Summary Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

6 Mdule 1 Summary ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events Mdule 2.3 A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin Mdule 2.1 A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.2 6

7 Mdule 1 Summary Check Mdule 2.2 Summary The addendum aims t imprve the planning, design, analysis and interpretatin f clinical trials. Clear trial bjectives shuld be translated int key scientific questins f interest by defining suitable estimands. An estimand defines the target f estimatin fr a particular trial bjective (i.e. what is t be estimated ). 7

8 Mdule 1 Summary Check Mdule 2.1 Summary The addendum aims t imprve the planning, design, analysis and interpretatin f clinical trials. Withut a precise descriptin f the trial bjective and the treatment effect that is targeted fr testing and estimatin there is a risk that: the study will nt be designed apprpriately t address its bjective; the statistical analyses will be misaligned t the trial bjective and the target f estimatin; the treatment effect that is reprted will be incrrectly interpreted, which risks misleading decisin makers. 8

9 Mdule 1 Summary Check Mdule 2.2 Summary This addendum presents a structured framewrk t link trial bjectives t a suitable trial design and tls fr estimatin and hypthesis testing. Trial bjective Estimand Target f estimatin = WHAT TO ESTIMATE Methd f estimatin = HOW TO ESTIMATE Main estimatr Main estimate 9

10 Mdule 1 Summary Check Mdule 2.2 Summary The addendum aims t facilitate dialgue regarding the treatment effects that a clinical trial shuld seek t estimate: between disciplines (medics, statisticians, etc). between spnsr and regulatr. Having clarity in the trial bjectives when describing the treatment effect f interest at the planning stage shuld infrm apprpriate chices abut trial design, data cllectin and statistical analysis. 10

11 Mdule 1 Summary Check Mdule 2.3 Summary The descriptin f an estimand will nt be cmplete withut reflecting hw ptential intercurrent events are addressed in the scientific questin f interest. Intercurrent events have the ptential t ccur after treatment initiatin and either preclude bservatin f the variable r affect its interpretatin, e.g.: use f an alternative treatment, perhaps a rescue medicatin; discntinuatin f treatment; terminal events such as death. Study discntinuatin, lss-t-fllw-up r ther missing data are nt intercurrent events and are nt reflected in the estimand, but instead represent limitatins t the data t be addressed in the analysis. 11

12 Mdule 1 Summary Check Mdule 2.3 Summary Different strategies are available fr hw t address ptential intercurrent events t reflect the scientific questin f interest. The chice f strategy fr each intercurrent event shuld be the subject f multi-disciplinary discussin between, e.g. statisticians and clinicians, and discussin between spnsr and regulatr. The disease setting and the aim f treatment will influence the chice f strategy. Different strategies can be used alne r in cmbinatin t address multiple different intercurrent events. 12

13 Mdule 1 Summary Check Mdule 2.4 Summary Having specified an estimand (=WHAT TO ESTIMATE), the addendum addresses impact n trial design, cnduct and analysis (=HOW TO ESTIMATE). In respect f estimatin, the addendum calls fr greater precisin n what is labelled as missing data. Specifically, having clarity in the estimand gives a basis fr planning which data need t be cllected and hence which data, when nt cllected, present a missing data prblem t be addressed. 13

14 Mdule 1 Summary Check Mdule 2.5 Summary The addendum gives a mre precise fcus t requirements fr sensitivity analysis. With an agreed estimand, and a pre-specified statistical analysis that is aligned t that estimand, sensitivity analysis can fcus n sensitivity t deviatins frm assumptins in respect f a particular analysis, rather than sensitivity t the chice f analytic apprach. 14

15 Mdule 1 Summary Check Mdule 2.6 Summary The addendum calls fr changes in trial dcumentatin. Estimands shuld be defined and explicitly specified in the clinical trial prtcl. The prtcl and the statistical analysis plan shuld pre-specify the main estimatr fr each estimand, tgether with a suitable sensitivity analysis t explre the rbustness under deviatins frm its assumptins. 15

16 Next mdule: 2.1. Intrductin Understanding treatment effects and mtivatin fr the ICH E9(R1) addendum. Scpe f the dcument and examples. Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 16

17 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 2.1: Intrductin Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

18 Mdule 2.1 Intrductin Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

19 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule 2.1 Intrductin This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

20 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule 2.1 Intrductin These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

21 Mdule 2.1 Intrductin Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

22 Mdule 2.1 Intrductin ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events Mdule 2.3 A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin Mdule 2.1 A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.2 6

23 Outline f Mdule 2.1 Understanding treatment effects Cncerns with current practice that mtivate the guidance Scpe f the addendum t ICH E9 Examples ICH E9(R1) Step 2 Training Material Mdule 2.1 Intrductin 7

24 Mdule 2.1 Intrductin Objectives f Mdule 2.1: Intrduce the purpse f the addendum, describing the imprtance f understanding and accurately quantifying treatment effects. Explain cncerns with the misalignment f trial bjectives, design and analysis in current practice. Intrduce the cncept f intercurrent events as events that cmplicate the descriptin and interpretatin f treatment effects. Examples are given. Intrduce a cherent framewrk, including: the intrductin f estimands; a revised definitin fr sensitivity analysis. 8

25 ICH E9(R1) Training Material Mdule 2.1 Intrductin Example 2: Chrnic cnditins Specifically, a treatment effect is estimated under ITT: Regardless f adherence, use f ther medicatins r change in backgrund medicatin. This will nt necessarily islate any adverse (r beneficial) effect f the medicine itself n cardivascular utcmes. Understanding What t d instead? The framewrk at least prvides a basis fr discussin f alternative appraches that might prvide a mre relevant basis fr decisin making. treatment effects ITT: Intentin-T-Treat 9

26 Mdule 2.1 Intrductin Understanding treatment effects Fr regulatry apprval a medicinal prduct shuld have therapeutic efficacy and a psitive risk-benefit. In additin t evidence that is statistically cmpelling evidence f efficacy, assessment f efficacy cnsiders the magnitude f the beneficial treatment effects. Treatment effects are estimated frm clinical trials. The treatment effects f interest shuld be specified and agreed befre chices are made designing a clinical trial t estimate them. 10

27 Mdule 2.1 Intrductin Understanding treatment effects Treatment effect: hw the utcme f treatment cmpares t what wuld have happened t the same subjects under different treatment cnditins: e.g. difference between treatment A and n treatment; e.g. difference between treatment A and treatment B. Which difference? Let s illustrate with a trial in Type II Diabetes Mellitus: If we specify a scientific questin f interest as the treatment difference between treatment and n treatment n HbA1c at Week 24 there is still ambiguity. The next slides explain why there is ambiguity HbA1c: Glycated haemglbin 11

28 Mdule 2.1 Intrductin Understanding treatment effects Cnsider a medicine fr Type II Diabetes Mellitus. What happens in clinical practice (and in clinical trials)? Sme patients will tlerate a medicine and adhere t its administratin schedule, thers will nt. Sme subjects will require changes in dse f cncmitant medicatin r administratin f additinal medicatin (e.g. rescue medicatin, treatment switch, etc.), thers will nt. In a ppulatin r in a clinical trial 12

29 Mdule 2.1 Intrductin Understanding treatment effects: Cnsider a medicine fr Type II Diabetes Mellitus. What happens in clinical practice (and in clinical trials)? Sme patients will tlerate a medicine and adhere t its administratin schedule, thers will nt. Sme subjects will require changes in dse f cncmitant medicatin r administratin f additinal medicatin (e.g. rescue medicatin, treatment switch, etc.), thers will nt. Sme patients will tlerate and adhere t the treatment, thers will nt 13

30 Mdule 2.1 Intrductin Understanding treatment effects: Cnsider a medicine fr Type II Diabetes Mellitus. What happens in clinical practice (and in clinical trials)? Sme patients will tlerate a medicine and adhere t its administratin schedule, thers will nt. Sme subjects will require changes in dse f cncmitant medicatin r administratin f additinal medicatin (e.g. rescue medicatin, treatment switch, etc.), thers will nt. Sme patients will require additinal medicatin, thers will nt Different treatment effects can be cnstructed. 14

31 Mdule 2.1 Intrductin Understanding treatment effects: Multiple definitins f treatment effects Check draft addendum sectin A.3.2! Sme patients will tlerate and adhere t the treatment, thers will nt Different measures f effect f treatment n HbA1c at week 24 regardless f adherence (i.e. whether the patient is able t remain n treatment). r in the hypthetical cnditin that all patients culd adhere t treatment. r in the strata f this ppulatin that can adhere t treatment. 15

32 Mdule 2.1 Intrductin Understanding treatment effects: Multiple definitins f treatment effects Check draft addendum sectin A.3.2! Sme patients will require additinal medicatin, thers will nt Different measures f effect f treatment n HbA1c at week 24 regardless f whether additinal medicatin is used. r in the hypthetical cnditin that additinal medicatin was nt available. r in the strata f this ppulatin that d nt require additinal medicatin. 16

33 Mdule 2.1 Intrductin Understanding treatment effects: Check draft addendum sectin A.3.2! Nt all alternatives can be reliably estimated. Nt all alternatives will be equally acceptable fr regulatry decisin making! 17

34 Mdule 2.1 Intrductin Understanding treatment effects: Intercurrent events ccur after treatment initiatin and either preclude bservatin f the variable r affect its interpretatin. Multiple events may need t be cnsidered in the same ppulatin, and even fr the same subject. Sme patients will tlerate the treatment, thers will nt Sme patients will require rescue medicatin, thers will nt 18

35 Mdule 2.1 Intrductin Understanding treatment effects: The key pint is that multiple, different treatment effects can be cnsidered. Befre designing and analysing a clinical trial it shuld be clear which treatment effects are f interest: fr regulatry decisin making; fr ptimal cmmunicatin f treatment effects t patients, prescribers and ther stakehlders. 19

36 Mdule 2.1 Intrductin Understanding treatment effects: Multiple different treatment effects can be cnsidered What regulatry cntext is already available n the questin f defining treatment effects? ICH E9 includes a reference t a treatment plicy (included in the intentin t treat principle), but n alternatives: ( ) the effect f a treatment plicy can be best assessed by evaluating n the basis f the intentin t treat a subject (i.e. the planned treatment regimen) rather than the actual treatment given. It has the cnsequence that subjects allcated t a treatment grup shuld be fllwed up, assessed and analysed as members f that grup irrespective f their cmpliance t the planned curse f treatment. Intentin-t-treat principle definitin, ICH E9 Glssary 20

37 Mdule 2.1 Intrductin Understanding treatment effects: Multiple different treatment effects can be cnsidered Treatment plicy is based n assessments regardless f what happens t patients (discntinuatin f treatment, use f additinal medicatins etc.). Data frm thse assessments are used in the statistical analysis fr measuring treatment effects. Is that what we want t knw fr decisin making? There fllws a case study, purely fr illustrating that: multiple, different treatment effects can be described. prblems arise when the treatment effect f interest is nt defined and agreed in advance. 21

38 Mdule 2.1 Intrductin Example: Type II diabetes mellitus Primary endpint: Change in HbA1c frm baseline t 24 weeks. Applicant: Estimand nt stated Data cllected after initiatin f rescue medicatin were excluded frm the analysis. LOCF used fr imputatin. Regulatr: Target f estimatin and analytical apprach cnsidered While FDA has implicitly endrsed LOCF imputatin fr diabetes trials in the past, there is nw mre awareness in the statistical cmmunity f the limitatins f this apprach. Instead I have included a sensitivity analysis in which the primary HbA1c utcmes are used regardless f rescue treatment, and n statistical adjustment is made fr rescue. This apprach is als imperfect, but it cmes clser t being a true intent-t-treat (ITT) analysis... HbA1c: Glycated haemglbin LOCF: Last bservatin carried frward 22

39 Mdule 2.1 Intrductin Example: Type II diabetes mellitus Different perspectives n the inclusin f data: Applicant: Remve data after initiatin f rescue medicatin, and impute. Use f rescue medicatin FDA: Include all data regardless f initiatin f rescue medicatin Use f rescue medicatin In this case, absence f an agreed treatment effect f interest led t a primary analysis that was nt aligned t the treatment effect f interest preferred by the regulatr. ITT: Intentin-t-treat ITT principle fllwed up, assessed and analysed as members f that grup irrespective f their cmpliance t the planned curse f treatment requires a cmparisn f treatment plicies dapagliflzin plus rescue versus cntrl plus rescue. 23

40 Mdule 2.1 Intrductin Example: Type II diabetes mellitus The applicant had nt specified the treatment effect f interest: It shuld nt be the chices fr data cllectin and data analysis that determine the questin f interest! The chice f trial design and data cllectin might have resulted in difficulties fr estimatin r inadequate statistical pwer fr the analysis, and differences in interpretatin f the trial data. This illustrates the imprtance n reaching agreement ver what t estimate: the estimand. 24

41 Mdule 2.1 Intrductin Estimand Estimand Is the target f estimatin t address the scientific questin f interest psed by the trial bjective. Attributes f an estimand include the ppulatin f interest, the variable (r endpint) f interest, the specificatin f hw intercurrent events are reflected in the scientific questin f interest, and the ppulatinlevel summary fr the variable. Estimand definitin, ICH E9(R1) Draft addendum 25

42 Mdule 2.1 Intrductin Example: Type II diabetes mellitus In this case FDA and Applicant use different appraches t deal with the use f rescue medicatin. We can identify tw different treatment effects: This is an intercurrent event. t assess the treatment effect if rescue medicatin is nt available ; t assess the treatment effect regardless f whether rescue medicatin is used. These are apprpriately thught f as different questins (estimands) and nt tw different answers t the same questin. 26

43 Intercurrent events ICH E9(R1) Step 2 Training Material Mdule 2.1 Intrductin Intercurrent events Events that ccur after treatment initiatin and either preclude bservatin f the variable r affect its interpretatin. Intercurrent events definitin, ICH E9(R1) Draft addendum These events (e.g. death) that preclude the bservatin f the variable, shuld nt be cnfused with missing data resulting frm lss t fllw-up! 27

44 Mdule 2.1 Intrductin Check draft addendum sectin A.3.2! Strategies t address intercurrent events A strategy reflects the chice made n hw t address intercurrent events, in rder t describe the treatment effect that is targeted. The addendum intrduces (at least) five strategies that can be used alne r in cmbinatin t address multiple different intercurrent events. Treatment plicy Principal stratum Cmpsite While n treatment Hypthetical 28

45 ICH E9(R1) Training Material Mdule 2.1 Intrductin Example 2: Chrnic cnditins Specifically, a treatment effect is estimated under ITT: Regardless f adherence, use f ther medicatins r change in backgrund medicatin. This will nt necessarily islate any adverse (r beneficial) effect f the medicine itself n cardivascular utcmes. Cncerns with What t d instead? The framewrk at least prvides a basis fr discussin f alternative appraches that might prvide a mre relevant basis fr decisin making. current practice ITT: Intentin-T-Treat 29

46 Mdule 2.1 Intrductin Cncerns with current practice Currently: Targets f estimatin that are nt clearly stated and cannt necessarily be inferred frm infrmatin in the study prtcl and statistical analysis plan. Chices are made fr data handling and statistical analysis that are nt cnsistent with the treatment effect f interest Endpint Statistical analysis Ppulatin Missing data Practice shuld be reversed: the target f estimatin shuld be clear frm the study prtcl; The statistical analysis shuld be aligned t the agreed target f estimatin. 30

47 Mdule 2.1 Intrductin Cncerns with current practice Use f the Intentin-t-treat principle: ITT is mentined in prtcls, statistical analysis plans and trial reprts, but nly as a way f specifying which patients are included in the analysis set, and nt t reflect the principle that patients will be fllwed-up regardless f their cmpliance t the planned curse f treatment. Lack f clarity exists in the majrity f clinical trials ver which treatment effect is being estimated: if it is nt aligned t the ITT principle and treatment plicy, then what? Estimating smething ther than an effect aligned t the ITT principle might be acceptable, but the alternative must be precisely specified and agreed. ITT: Intentin-t-treat 31

48 Mdule 2.1 Intrductin Cncerns with current practice Missing Data In additin t study discntinuatins, patients wh discntinue assigned treatment, start anther treatment, r die are all treated generically as missing data causing prblems fr analysis and inference. Sme methds fr handling f missing data in current practice mis-represent treatment effects that are nevertheless used in drug licensing decisins and reprted t prescribers. E.g. mdelling t address the exclusin f data fr patients wh discntinue treatment, based n thse patients wh d nt, when estimating a treatment effect aligned t the ITT principle. ITT: Intentin-t-treat 32

49 Mdule 2.1 Intrductin Cncerns with current practice Targets f estimatin Targets f estimatin, nce identified, might nt be relevant t decisin makers (e.g. regulatrs, HTA bdies, payers, prescribers and patients): Different treatment effects might be relevant t different decisin makers. External validity There are cncerns that clinical trials are less representative if the spnsr tries t avid the ccurrence f, r the impact f, intercurrent events that will ccur in clinical practice, e.g. patients discntinuing frm treatment r using additinal medicatins. HTA: Health technlgy assessment 33

50 Mdule 2.1 Intrductin Cncerns with current practice Sensitivity analysis Analyses currently labelled as sensitivity analyses can in fact have different targets f estimatin (estimands), s that cnsistent results between analyses shuld nt necessarily be expected. Requirements that a brad range f sensitivity analyses all give cnsistent results might unnecessarily increase the hurdle fr demnstratin f therapeutic efficacy. 34

51 Mdule 2.1 Intrductin Cncerns with current practice Analysis sets Trials ften include repeated measurements n the same subject and the Full Analysis Set is incrrectly specified. ICH E9 strngly recmmends that analysis f superirity trials be based n the full analysis set, but eliminatin f planned measurements n sme subjects can have similar cnsequences t excluding subjects altgether frm the analysis. Per-prtcl analysis is subject t severe bias: can the need t explre the impact f prtcl vilatins and deviatins be addressed in a way that is less biased and mre interpretable than naïve analysis f the per-prtcl set? The treatment effect f interest shuld be defined in a way that determines the ppulatin f subjects t be included in the estimatin and the bservatins frm each subject t be included in the analysis cnsidering the ccurrence f intercurrent events. 35

52 Cncerns with current practice Bad drugs might appear gd and gd drugs might appear bad! Bad drugs might appear gd: ICH E9(R1) Step 2 Training Material Mdule 2.1 Intrductin Cnsider a drug fr a chrnic cnditin fr which efficacy and txicity are related. Patients wh benefit are mre likely t experience txicity. In a trial sme patients expsed t the drug will benefit n mre than patients expsed t placeb; thers will benefit but need t discntinue frm treatment due t txicity. Even if n-ne benefits in the lng term, it can be imagined that chices made n which data t cllect and include, and the analytical apprach, can either create r exaggerate a psitive treatment effect. 36

53 Mdule 2.1 Intrductin Cncerns with current practice Bad drugs might appear gd and gd drugs might appear bad! [illustratin cntinued] Gd drugs might appear bad: Cnsider a placeb-cntrlled trial testing a medicine that is, in fact, effective, where patients can use rescue medicatin when experiencing inadequate respnse. Imagine that use f rescue ccurs markedly mre n placeb than n experimental treatment and that rescue medicatin is als effective. A treatment effect defined regardless f whether additinal medicatin is used and estimated accrdingly, is likely t be lwer than the effect f treatment in the hypthetical cnditin that additinal medicatin was nt available r in the strata f this ppulatin that d nt require additinal medicatin (see Slide 16). 37

54 ICH E9(R1) Training Material Mdule 2.1 Intrductin Example 2: Chrnic cnditins Specifically, a treatment effect is estimated under ITT: Regardless f adherence, use f ther medicatins r change in backgrund medicatin. This will nt necessarily islate any adverse (r beneficial) effect f the medicine itself n cardivascular utcmes. Scpe f the What t d instead? The framewrk at least prvides a basis fr discussin f alternative appraches that might prvide a mre relevant basis fr decisin making. addendum t ICH E9 ITT: Intentin-T-Treat 38

55 Mdule 2.1 Intrductin Framewrk A framewrk and language are intrduced t: Prmte alignment between trial bjectives, design (data cllectin), cnduct, analysis and inference; Prmte understanding that trial bjectives cannt be translated int estimands withut reflecting hw ptential intercurrent events are addressed in the scientific questin f interest; Prmte discussin f different strategies t handle intercurrent events in rder t identify and describe the treatment effects that reflect the scientific questins f interest. Clinical Trial 39

56 Mdule 2.1 Intrductin Framewrk A framewrk and language are intrduced t: Define a treatment effect f interest - befre a trial is designed and cnducted - that is relevant t use f a medicine in clinical practice; Highlight the imprtance f cnsidering whether a main analysis will derive an estimate which is reliable fr inference; Re-define missing data; Re-define sensitivity analysis and the regulatry assessment f rbustness; Intrduce supplementary analysis as any ther analysis cnducted t fully investigate and understand the trial data. 40

57 Opprtunities ICH E9(R1) Step 2 Training Material Mdule 2.1 Intrductin Aligning drug develpers and regulatry bdies expectatins fr the target treatment effect in advance has the ptential t give: Mre meaningful descriptins f treatment effects fr licensing and prescribing decisins; Clinical trials with designs that are aligned t agreed bjectives; Increased transparency with respect t data analysis and inference; Mre predictable regulatry assessment prcedures. 41

58 Mdule 2.1 Intrductin Scpe The ICH E9(R1) addendum builds n ICH E9: i.e. its primary fcus is cnfirmatry clinical trials; clarity n treatment effects f interest fr regulatry decisin making is demanded. Hwever, the framewrk is applicable whenever treatment effects are t be estimated and tested: in ther phases f clinical develpment, including pst-authrisatin; in clinical trials and in bservatinal studies; regardless f therapeutic area r experimental design. 42

59 ICH E9(R1) Training Material Mdule 2.1 Intrductin Example 2: Chrnic cnditins Specifically, a treatment effect is estimated under ITT: Regardless f adherence, use f ther medicatins r change in backgrund medicatin. This will nt necessarily islate any adverse (r beneficial) effect f the medicine itself n cardivascular utcmes. Examples What t d instead? The framewrk at least prvides a basis fr discussin f alternative appraches that might prvide a mre relevant basis fr decisin making. The need fr defining estimands ITT: Intentin-T-Treat 43

60 Mdule 2.1 Intrductin Example 1: End f life in cancer patients Check Mdule 3: Generic example Cntext: Fr end f life cancer patients, medicines might be develped and administered t maintain weight, functining and quality f life fr the duratin f the patient s remaining life. Measures f efficacy: Bdy weight, bdy cmpsitin (DEXA), hand-grip strength and QL assessment scales. Intercurrent event: A nn-negligible prprtin f patients will die, which needs t be cnsidered in defining the treatment effect f interest. DEXA: Dual-energy X-ray absrptimetry QL: Quality f life 44

61 Mdule 2.1 Intrductin Check Mdule 3: case studies Example 1: End f life in cancer patients This is based n a real example where, withut statement f the estimand (treatment effect f interest) deaths were handled as missing data and utcmes imputed / mdelled accrding t the analysis plan; interpretatin f trial results was difficult; estimates f effect calculated n that basis had questinable relevance t effects in clinical practice; trying t identify an utcme at Week 12 fr the statistical analysis, fr the patients wh had previusly died, was arguably meaningless. What treatment effect shuld be f interest cnsidering that sme patients will die within 12 weeks f initiating treatment? 45

62 Mdule 2.1 Intrductin Example 2: Cardivascular safety Cntext: In sme chrnic cnditins (e.g. diabetes) current practice is t cnduct large utcme trials t exclude large harmful effects n cardivascular safety, with the ptential t demnstrate a beneficial effect. E.g. patients are randmised t a treatment vs. placeb n tp f a backgrund regimen that might differ between patients. Measures f efficacy: Patient are fllwed t bserve MACE events, ften ver a perid f years. MACE: Majr adverse cardiac events 46

63 Mdule 2.1 Intrductin Example 2: Cardivascular safety Intercurrent events: Patients discntinue assigned treatment, initiate new treatment and change backgrund treatment. Analyses can be cnducted, largely in line with the ITT principle (i.e. subjects are fllwed up, assessed and analysed irrespective f their cmpliance t the planned curse f treatment) in respect f these intercurrent events. Estimand: (E.g.) Difference between treatment and placeb in incidence f MACE regardless f whether patients discntinue assigned treatment, initiate new treatment r change backgrund treatment. Will this prvide an estimate f a treatment effect that is relevant t understanding the cardivascular risk f the treatment? Are there better strategies fr addressing these intercurrent events that give greater insights int the safety prfile f the treatment? ITT: Intentin-t-treat MACE: Majr adverse cardiac events 47

64 Next mdule: 2.2. Framewrk Implicatins n design and cnduct f clinical trials and in the perfrmance f statistical analyses Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 48

65 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 2.2 Framewrk Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

66 Mdule Framewrk Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

67 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule Framewrk This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

68 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule Framewrk These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

69 Mdule Framewrk Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

70 Mdule Framewrk ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events Mdule 2.3 A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin Mdule 2.1 A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.2 6

71 Mdule Framewrk Outline f Mdule 2.2 A new framewrk fr clinical trials Alignment between trial bjective, design, planning, cnduct, analysis and interpretatin Hw this framewrk can imprve discussins between spnsrs and regulatrs n the suitability f designs and the interpretatin f results 7

72 Mdule Framewrk A new framewrk Clear trial bjectives shuld be translated int key scientific questins f interest by defining suitable estimands. Clear trial bjective Key scientific questin f interest Estimand ( what is t be estimated ) 8

73 Mdule Framewrk Aligning target f estimatin, methd f estimatin, and sensitivity analysis, fr a given trial bjective Trial bjective Estimand Target f estimatin = WHAT Methd f estimatin = HOW Main estimatr Main estimate 9

74 Mdule Framewrk Aligning target f estimatin, methd f estimatin, and sensitivity analysis, fr a given trial bjective Methd f estimatin = HOW Trial bjective Estimand Main estimatr Main estimate Target f estimatin = WHAT The main estimatr will be underpinned by certain assumptins. T explre the rbustness f inferences frm the main estimatr t deviatins frm its underlying assumptins, sensitivity analysis shuld be cnducted, in frm f ne r mre analyses, targeting the same estimand. 10

75 Mdule Framewrk Aligning target f estimatin, methd f estimatin, and sensitivity analysis, fr a given trial bjective Trial bjective Estimand Target f estimatin = WHAT Methd f estimatin = HOW Main estimatr Sensitivity estimatr 1 Sensitivity estimatr 2 Main estimate Sensitivity estimate 1 Sensitivity estimate 2 Sensitivity analysis 11

76 Mdule Framewrk Aligning target f estimatin, methd f estimatin, and sensitivity analysis, fr a given trial bjective In general, it is imprtant t prceed sequentially. The trial bjective shuld determine the chice f estimands and the estimands shuld determine the chice f estimatrs, nt the reverse. Trial bjective Estimand Main estimatr Main estimate Where significant issues exist t derive a reliable estimate fr a particular estimand, the trial bjectives need t be recnsidered frm tp-dwn t main estimatr (green arrws). The main estimatr shuld never define the trial bjective frm bttm-up (red arrws). 12

77 A new framewrk ICH E9(R1) Step 2 Training Material Mdule Framewrk Clinical Trial Apprpriate estimands will be the main determinant fr aspects f trial design, cnduct and analysis. 13

78 A new framewrk ICH E9(R1) Step 2 Training Material Mdule Framewrk A cmmn language and cmmn understanding f this framewrk will help spnsrs planning trials and regulatrs in their reviews, enhancing the interactins between these parties when discussing the suitability f designs, and the interpretatin f results, t supprt drug licensing. Regulatrs + ESTIMAND &?% Spnsr 14

79 Next mdule: 2.3. Estimands Descriptin, strategies and cnstructin f estimands Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 15

80 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 2.3: Estimands Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

81 Mdule Estimands Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

82 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule Estimands This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

83 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule Estimands These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

84 Mdule Estimands Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

85 ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis ICH E9(R1) Step 2 Training Material Mdule Estimands Mdule 2.1 A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.3 Mdule 2.2 6

86 Mdule Estimands Outline f Mdule 2.3 Fur attributes (A thrugh D) that tgether describe an estimand Strategies fr addressing intercurrent events General cnsideratins fr the cnstructin f estimands Therapeutic and experimental cnsideratins fr the cnstructin f estimands 7

87 Mdule 2 A.3.1. Descriptin A.3.2 Strategies fr addressing intercurrent events A.3.3 Cnstructin f estimands 8

88 Mdule Estimands Quantificatin f treatment effect A central questin fr drug develpment and licensing... Hw des the utcme f a treatment cmpares t what wuld have happened t the same subjects under different treatment cnditins? e.g. had they nt received the treatment r had they received a different treatment. Intercurrent events need t be cnsidered. The ccurrence f intercurrent events may depend n treatment cnditins (e.g. had they nt received the treatment r had they received a different treatment) which can impact data cllected t assess clinical utcmes. An estimand defines in detail what needs t be estimated t address a specific scientific questin f interest. A descriptin f an estimand includes fur attributes. 9

89 Mdule Estimands Descriptin f an estimand Ppulatin Variable Ppulatin-level summary % The descriptin f an estimand will nt be cmplete withut reflecting hw ptential intercurrent events are addressed in the scientific questin f interest. Rescue medicatin Death 10

90 Mdule Estimands A. Ppulatin Patients targeted by the scientific questin B. Variable (r endpint) C. Intercurrent event The specificatin f hw t accunt fr intercurrent events t reflect the scientific questin f interest D. Ppulatin-level summary fr the variable Prvides, as required, a basis fr a cmparisn between treatment cnditins Measure(s) required t address the scientific questin (t be btained fr each patient) 11

91 Mdule Estimands A. Ppulatin B. Variable Tgether these attributes describe the C. Intercurrent event The specificatin f hw t accunt fr intercurrent events t reflect the scientific questin f interest Patients targeted by the scientific questin (r endpint) estimand Measure(s) required t address the scientific questin (t be btained fr each D. patient) defining the target Ppulatin-level f estimatin. summary fr the variable Prvides, as required, a basis fr a cmparisn between treatment cnditins 12

92 Mdule Estimands Descriptin f an estimand A. Ppulatin Patients targeted by the scientific questin The ppulatin is typically characterised thrugh inclusin/exclusin criteria in the study prtcl. In sme cases a subgrup is f interest defined by a baseline characteristic; defined in terms f a ptential intercurrent event, fr example, the stratum f patients wh can tlerate and remain n treatment. Nte the imprtant difference in hw the subgrup (baseline characteristics) and the stratum (ptential intercurrent event nce treatment is received) are defined. 13

93 Mdule Estimands Descriptin f an estimand B. Variable (r endpint) Measure(s) required t address the scientific questin (t be btained fr each patient) HbA1c: Glycated haemglbin AUC: Area under the curve HbA1c The variable typically cnsists f measurements taken: e.g. bld pressure; functins theref: e.g. change frm baseline t ne year in HbA1c; quantities related t bserved events: e.g. time f death, number f relapses. The variable may als be used t address intercurrent events such as discntinuatin f interventin using measurements taken prir t discntinuatin f treatment (e.g., AUC f HbA1c until discntinuatin); r using cmpsites (e.g., treatment failure defined as nn-respnse r treatment discntinuatin). 14

94 Mdule Estimands Descriptin f an estimand Check definitin f IE in Mdule 2.1 C. Intercurrent event The specificatin f hw t accunt fr intercurrent events t reflect the scientific questin f interest Rescue medicatin Intercurrent events can present in multiple frms and can affect the interpretatin f the variable. Clinical trials are typically faced with mre than ne type f intercurrent event. The set f intercurrent events fr cnsideratin will depend n the specific therapeutic setting and trial bjective. Death IE: Intercurrent event 15

95 Mdule Estimands Descriptin f an estimand Intercurrent events Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Treatment discntinuatin due t adverse events Treatment discntinuatin due t lack f efficacy Use f rescue medicatin Death Treatment switch Change in backgrund therapy Study discntinuatin? Randmisatin TIMELINE Data cllectin fr the variable 16

96 Mdule Estimands Descriptin f an estimand C. Intercurrent event The specificatin f hw t accunt fr intercurrent events t reflect the scientific questin f interest Rescue medicatin Death Hw t accunt fr intercurrent events? Fr example, accunting fr it as part f the variable (cmpsite strategy, while-n-treatment strategy); by disregarding its ccurrence / as part f the treatment (treatment-plicy strategy); as part f the ppulatin (principal stratificatin strategy) r; as mdel-based predictins under the riginally randmised treatment (hypthetical strategy). 17

97 Missing data ICH E9(R1) Step 2 Training Material Mdule Estimands Intercurrent events are nt a missing data prblem. Lss-t-fllw-up is nt generally regarded as an intercurrent event. Indeed missing data and lss-t-fllw-up are irrelevant t the cnstructin f the estimand. Missing data Data that wuld be meaningful fr the analysis f a given estimand but were nt cllected. They shuld be distinguished frm data that d nt exist r data that are nt cnsidered meaningful because f an intercurrent event. Missing data definitin, ICH E9(R1) Draft addendum 18

98 Mdule Estimands Descriptin f an estimand D. Ppulatin-level summary fr the variable Prvides, as required, a basis fr a cmparisn between treatment cnditins. HbA1c: Glycated haemglbin % It culd be, fr example, a mean r a prprtin r, pssibly, a hazard rate. In case f treatment cmparisns, examples are: the difference in mean change frm baseline t ne year in HbA1c, r the difference r rati in the prprtin f subjects meeting specified criteria, under tw different treatment cnditins. a hazard rati, t-year event-rate difference r restricted mean survival time difference. 19

99 Mdule Estimands A. Ppulatin Patients targeted by the scientific questin independently. D. Ppulatin-level summary fr the variable Prvides, as required, a basis fr a cmparisn between treatment cnditins B. Variable (r endpint) The estimand attributes A thrugh D are C. Intercurrent inter-related event and shuld nt be cnsidered The specificatin f hw t accunt fr intercurrent events t reflect the scientific questin f interest Measure(s) required t address the scientific questin (t be btained fr each patient) 20

100 Mdule 2 A.3.1. Descriptin A.3.2 Strategies fr addressing intercurrent events A.3.3 Cnstructin f estimands 21 21

101 Mdule Estimands Hw are ptential intercurrent events reflected in the scientific questin f interest? 4 Attributes Treatment plicy Cmpsite Hypthetical 5 Strategies Principal stratum While n treatment 22

102 Mdule Estimands Strategies fr addressing intercurrent events At least 5 Strategies t cnsider when addressing different intercurrent events. A strategy is chsen fr each intercurrent event t reflect the scientific questin f interest; different strategies can be used fr different intercurrent events. The relevance f each strategy will depend n the therapeutic and experimental cntext Nt all strategies will be equally acceptable fr regulatry decisin making! 23

103 Mdule Estimands Hw are ptential intercurrent events reflected in the scientific questin f interest? Let s take an example Drug X Indicated fr a chrnic, nn-lifethreatening disease Respnse t treatment: mnitred mnthly (cntinuus measurement). Main scientific questin: cmparisn f Drug X t placeb at mnth 6 best addressed by a randmised clinical trial. Intercurrent events: Use f placeb in the clinical trial is cnsidered ethical but nly if prvisin is made fr subjects t discntinue their treatment and use rescue medicatin due t lack f efficacy (after which it is still pssible t cllect data fr the variable). It is als pssible t cllect data after ther intercurrent events such as discntinuatin f treatment due t an adverse event, but nt fr intercurrent events such as death (cnsidered very unlikely in this setting). 24

104 Mdule Estimands If we assume that n intercurrent events ccur (unrealistic) example Estimand: Difference in means between treatment cnditins in the change frm baseline t mnth 6 in the designated measurement in the targeted patient ppulatin. Let s cnsider 3 patients and what culd happen if n intercurrent events ccurred (this slide), and under each strategy (fllwing slides). Patient 1 Patient 2 Baseline measurement 6 mnths N intercurrent event Treatment cmplete N intercurrent event Treatment cmplete Legend: 6-mnth value has been cllected Part f patient time curse cnsidered 25

105 Mdule Estimands Nw assuming that there are intercurrent events 26

106 Mdule Estimands 1. Treatment-plicy strategy Strategy labels are just fr ease f reference In this strategy, the ccurrence f the intercurrent event is irrelevant: the data cllected fr the variable f interest are used regardless f whether r nt the intercurrent event ccurs. Fr example, when specifying hw t accunt fr rescue medicatin as an intercurrent event, ccurrence f the intercurrent event is ignred (disregarded) and the bservatins cllected after use f rescue medicatin fr the variable f interest are used. In general, this strategy cannt be implemented when values fr the variable after the intercurrent event d nt exist fr all subjects. Fr example, an estimand based n this strategy cannt be cnstructed with respect t a variable that cannt be measured due t death. 27

107 Mdule Estimands 1. Treatment-plicy strategy - example Estimand: Difference in means between treatment cnditins in the change frm baseline t mnth 6 in the targeted patient ppulatin, regardless f whether rescue medicatin was used. If rescue medicatin (intercurrent event) is used Baseline measurement 6 mnths Patient 1 Patient 2 Patient 3 Start f rescue medicatin? N intercurrent event Treatment cmplete Intercurrent event N intercurrent event Treatment incmplete Legend:? Applying the treatment plicy strategy Patient 1 Patient 2 Patient 3 6-mnth value has been cllected 6-mnth value has nt been cllected, data are missing Patient lst t fllw-up Start f rescue medicatin? N intercurrent event Treatment cmplete 6-mnth value still cnsidered; IE disregarded N intercurrent event Patient included but data are missing Intercurrent event (IE) - in grey when disregarded Part f patient time curse cnsidered 28 Part f patient time curse nt bserved and needs t be imputed/predicted

108 Mdule Estimands 2. Cmpsite strategy Strategy labels are just fr ease f reference In this strategy, the ccurrence f the intercurrent event is taken t be a cmpnent f the variable, i.e. the intercurrent event is integrated with ne r mre ther measures f clinical utcme as the variable f interest. Fr example, the variable might be defined as a cmpsite f n use f rescue medicatin and a favurable clinical utcme, i.e. patient becmes a nn-respnder if they need t use rescue medicatin. Alternatively, fr a numerical variable, experiencing an intercurrent event might be ascribed an extreme unfavurable value and a suitable summary measure selected (e.g. median r trimmed mean). 29

109 Mdule Estimands 2. Cmpsite strategy Smetimes an event being cnsidered as intercurrent is itself the mst meaningful variable that can be measured fr quantifying the treatment effect f interest. This can be the case with death: the fact that a subject has died may be much mre meaningful than bservatins befre death, and bservatins after death will nt exist. 30

110 Mdule Estimands 2. Cmpsite strategy - example The estimand assesses the treatment effect based n a clinically meaningful change in the designated measurement in patients wh d nt take rescue medicatin. Applying the cmpsite strategy Baseline measurement 6 mnths Patient 1 Patient 2 Start f rescue medicatin This is nt the nly way t address intercurrent events using the cmpsite strategy; ther ways include trimmed means r quantiles. N intercurrent event + clinically meaningful change Intercurrent event; N need t cllect 6-mnthvalue Patient 3 N intercurrent event + change nt clinically meaningful Legend: 6-mnth value has been cllected and utcme is psitive 6-mnth value has been cllected and utcme is negative Part f patient time curse cnsidered Part f patient time curse nt cnsidered. Intercurrent event as part f the cmpsite variable. Time f intercurrent event marks the end f data cllectin. 31

111 Mdule Estimands 3. Hypthetical strategy Strategy labels are just fr ease f reference In this strategy, a hypthetical scenari is envisaged in which the intercurrent event wuld nt ccur. Fr example, when rescue medicatin must be made available fr ethical reasns, a treatment effect f interest might cncern the utcmes if rescue medicatin had nt been available. The value t reflect that scientific questin f interest is that which the variable wuld have taken in the hypthetical scenari defined. In this example, the value t be cnsidered wuld have been the ne cllected if patients had nt had rescue medicatin available. By definitin, such value cannt be bserved but will need t be implicitly r explicitly predicted / imputed. 32

112 Mdule Estimands 3. Hypthetical strategy Imprtant t keep in mind The hypthetical scenari shuld cnsider reasnable situatins, e.g. a scenari where a txic medicine is cnsidered t be nn-txic is nt usually relevant fr decisin making. Care is required t precisely describe the hypthetical cnditins reflecting the scientific questin f interest in the cntext f the specific trial. 33

113 Mdule Estimands 3. Hypthetical strategy - example The estimand assesses the treatment effect in an alternative, hypthetical setting where rescue medicatin was nt available t subjects. Applying the hypthetical strategy Baseline measurement 6 mnths Patient 1 Patient 2 Start f rescue medicatin N intercurrent event - Treatment cmplete N need t cllect 6- mnth value Legend: 6-mnth value has been cllected and utcme is psitive N need t cllect 6-mnth value Part f patient time curse cnsidered Part f patient time curse nt bserved and needs t be imputed/predicted Intercurrent event hypthetically nt present. Time f intercurrent event marks the end f data cllectin. 34

114 Mdule Estimands 4. Principal stratum strategy Strategy labels are just fr ease f reference In this strategy, principal stratificatin is defined by a patient s ptential intercurrent events n either r bth treatments. It is a subset f the brader ppulatin; Fr example, patients wh can tlerate and remain n either treatment; the target ppulatin is then cnsidered t be the stratum in which an intercurrent event wuld nt ccur in either grup; A specific stratum r several strata culd be f interest, e.g. adherence t treatment regardless f adherence t cntrl. The scientific questin f interest relates t the treatment effect nly within that stratum / thse strata. Effects in principal strata shuld be clearly distinguished frm any type f subgrup r per-prtcl analyses where membership is based n the trial data. 35

115 Mdule Estimands 4. Principal stratum strategy It is nt pssible in general t identify these subjects directly, either in advance f the trial since the ccurrence f the intercurrent event cannt be perfectly predicted, r based n the data frm a parallel-grup randmised cntrlled trial because each patient will be bserved n ne treatment nly. 36

116 Placeb ICH E9(R1) Step 2 Training Material Mdule Estimands 4. Principal stratum strategy - example A given patient can receive either treatment r placeb. When receiving treatment sme patients will use rescue medicatin, thers nt. The same applies fr patients n placeb. The estimand assesses the treatment effect in the stratum f patients which wuld nt use rescue medicatin regardless t which treatment arm they wuld be assigned. Patients fall int exactly ne f these fur strata: S 00 : stratum f patients wh require rescue medicatin independently f treatment r placeb; S 01 : stratum f patients wh require rescue medicatin n placeb and d nt require it n treatment; S 10 : stratum f patients wh require rescue medicatin n treatment and d nt require it n placeb; S 11 : stratum f patients wh d nt require rescue medicatin independently f treatment r placeb. This is the nly stratum where the intercurrent event f use f rescue medicatin des nt ccur. A ppulatin can be defined by membership f ne r mre f these strata. Treatment Rescue medicatin N rescue medicatin Rescue medicatin S 00 S 01 N rescue medicatin S 10 S 11 37

117 Mdule Estimands 5. While n treatment strategy Strategy labels are just fr ease f reference In this strategy, respnse t treatment prir t the ccurrence f the intercurrent event is f interest. This culd be, fr example, the last measurement befre death (r ther intercurrent event) r at a pre-defined time-pint, whichever cmes first. If a variable is measured repeatedly, its values up t the time f the intercurrent event may be cnsidered t accunt fr the intercurrent event, rather than the value at the same fixed time pint fr all subjects. Fr example: - subjects with a terminal illness may discntinue a purely symptmatic treatment because they die, yet it is relevant t measure the success f the treatment based n the effect n symptms befre death. - subjects might discntinue treatment, and in sme circumstances it will be f interest t assess the risk f an adverse drug reactin during the perid f adherence t treatment. 38

118 Mdule Estimands 5. While n treatment strategy - example The estimand assesses the treatment effect n the variable measurement. The variable chsen here addresses the utcmes while being n treatment, i.e. befre start f rescue medicatin. Applying the while n treatment strategy Baseline measurement 6 mnths Patient 1 Patient 2 Start f rescue medicatin Difficulties arise in deriving an estimate that is reliable fr inference when fllw-up times are different between grups. N intercurrent event - Treatment cmplete Data cllected befre the ccurrence f the intercurrent event will be used t determine the variable Legend: End pint value has been cllected Part f patient time curse cnsidered Part f patient time curse nt cnsidered Time f intercurrent event marks end f data cllectin (merged with green dt). 39

119 Mdule Estimands Multiple intercurrent events example The strategies presented befre can be used alne r in cmbinatin t address multiple different intercurrent events. Returning t the example: Drug X, indicated fr the treatment f a chrnic, nn-life-threatening disease. Respnse t treatment: mnitred mnthly (cntinuus measurement). Main scientific questin: cmparisn f drug X t placeb at mnth 6. Intercurrent events: Use f placeb in the clinical trial is cnsidered ethical but nly if prvisin is made fr subjects t discntinue their treatment and use rescue medicatin due t lack f efficacy (after which it is still pssible t cllect data fr the variable). This is als the case after ther intercurrent events such as discntinuatin f treatment due t an adverse event, but nt fr intercurrent events such as death (cnsidered very unlikely in this setting). Secnd intercurrent event 40

120 Mdule Estimands Multiple intercurrent events example Treatment-plicy strategy t accunt fr bth intercurrent events: Estimand: Difference in means between treatment cnditins in the change frm baseline t mnth 6 in the targeted patient ppulatin, regardless f whether r nt rescue medicatin had been used and regardless f treatment discntinuatin due any adverse events. Applying treatment-plicy x treatment-plicy strategy Patient 1 Patient 2 Patient 3 Baseline Discntinuatin due t AE measurement Start f rescue medicatin 6 mnths N intercurrent event Treatment cmplete 6-mnth value still cnsidered; IE disregarded 6-mnth value still cnsidered; IE disregarded Legend: 6-mnth value has been cllected Part f patient time curse cnsidered IE Intercurrent events (in grey when disregarded) Intercurrent event 41

121 Legend: Multiple intercurrent events example 6-mnth value has been cllected N need t cllect 6-mnth value Part f patient time curse cnsidered ICH E9(R1) Step 2 Training Material Mdule Estimands Cmbinatin f hypthetical strategy and treatmentplicy strategy t accunt fr the tw intercurrent events: Estimand: Difference in means between treatment cnditins in the change frm baseline t mnth 6 in the targeted patient ppulatin had rescue medicatin nt been made available t subjects prir t mnth six and regardless f study treatment discntinuatin due t an adverse event. Applying hypthetical x treatment-plicy strategy Patient 1 Patient 2 Patient 3 Baseline Discntinuatin due t AE measurement Start f t rescue medicatin 6 mnths N intercurrent event Treatment cmplete N need t cllect 6- mnth value 6-mnth value still cnsidered; intercurrent event disregarded Part f patient time curse nt bserved and needs t be imputed/predicted 42 Intercurrent event hypthetically nt present. Time f intercurrent event marks the end f data cllectin. Intercurrent event (in grey when disregarded)

122 Mdule Estimands Multiple intercurrent events The definitin f a clinically meaningful estimand needs t encmpass all intercurrent events that are likely t ccur and are clinically relevant in a given clinical trial setting. The descriptin f the treatment effect being targeted cannt be fully understd withut cnsidering hw t address the intercurrent events in the estimand. Taking int accunt intercurrent events is equally imprtant fr the chices made abut the design, cnduct and statistical analysis. Cnsidering the five strategies discussed abve, all pssible cmbinatins f strategies fr tw types f intercurrent events can be cnsidered, althugh nt all cmbinatins will be clinically relevant. 43

123 Mdule Estimands Further cnsideratins n strategies The chice f strategies must be the bject f a multidisciplinary discussin in particular, between spnsrs and regulatrs. The descriptin f the preferred strategy fr handling each intercurrent event shuld be precisely defined in the study prtcl, as well as the reasns fr that chice. 44

124 Mdule 2 A.3.1. Descriptin A.3.2 Strategies fr addressing intercurrent events A.3.3 Cnstructin f estimands 45

125 Mdule 2 A.3.3 Cnstructin f estimands A General cnsideratins 46 46

126 Mdule Estimands Cnsidering intercurrent events Clinical Trial Each intercurrent event that may ccur in the clinical trial and that will affect the interpretatin f the results f the trial needs t be cnsidered explicitly in the cnstructin f the estimand. This will Unambiguusly describe the treatment effect f interest; Prmte the relevance f the treatment effect described t patients and physicians. 47

127 Mdule Estimands Cnsidering intercurrent events Clinical Trial But It s nt always pssible t fresee every relevant kind f intercurrent event at the planning stage. Trial reprting shuld then discuss nt nly the way unfreseen intercurrent events were handled in the analysis but als the effect n what the revised analysis estimates. 48

128 Mdule Estimands Cnstructin f an estimand It is a multi-disciplinary undertaking and shuld be the subject f discussin between spnsrs and regulatrs. Clinicians Spnsrs Objectives, estimands and designs f prspective CTs Regulatrs Clinical trial design and cnduct δ α Statisticians Other disciplines 49 CTs: Clinical Trials

129 Mdule Estimands Cnstructin f an estimand The cnstructin f an estimand shuld be: Cnsequent t the trial bjectives and shuld precede chices relating t data cllectin and analytic appraches; Clinically interpretable, in terms f the ppulatin and endpint, but als in terms f the strategies t accunt fr intercurrent events and, finally, the summary measure; Duly justified cnsidering the therapeutic setting and the treatment gals f the interventin, frm which the key scientific questins f interest can be derived. 50

130 Mdule Estimands Aviding r ver-simplifying this prcess risks misalignment between trial bjectives, trial design, data cllectin and statistical analysis! Clinical Trial 51

131 Mdule Estimands Cnstructin f an estimand: Hw d we d it? Trial bjective Estimand Main estimatr Main estimate Where significant issues exist t derive a reliable estimate fr a particular estimand, the trial bjectives need t be re-cnsidered frm tp-dwn t main estimatr (green arrws). The main estimatr shuld never define the trial bjective frm bttm-up (red arrws). 52

132 Mdule 2 A.3.3 Cnstructin f estimands A Cnsideratins f Therapeutic and Experimental Cntext 53

133 Mdule Estimands Imprtant t keep in mind The aim f the EWG was t develp and present a framewrk t facilitate these imprtant discussins and nt t give therapy-area specific recmmendatins. The pints raised n subsequent slides are fr reflectin and are nt designed t influence the preferred chice f strategy. EWG: ICH E9(R1) Expert Wrking Grup 54

134 What can influence the cnstructin f the estimand? Disease setting: Are alternative treatment ptins available? - E.g. fr glycaemic cntrl in Type II diabetes mellitus multiple therapies are licensed. Can individual respnse t treatment be mnitred ver time? - E.g. in hypertensin, bld pressure is mnitred frequently t assess respnse t treatment, inadequate respnse wuld be detected in a timely manner. Aim f treatment: ICH E9(R1) Step 2 Training Material Mdule Estimands Cntrlling symptms? - E.g. pain cntrl in the treatment f migraine. Mdifying the curse f disease r preventin f disease? - E.g. delay t the nset f dementia in prdrmal Alzheimer s disease. 55

135 Mdule Estimands Ntes abut the treatment-plicy strategy Rescue medicatin The treatment fails but values after rescue are still cnsidered (the intercurrent event is disregarded) Treatment plicy strategies might be mre generally acceptable t supprt regulatry decisin making. Als in settings where: Estimands based n alternative strategies might be cnsidered f greater clinical interest; N ther estimatrs can supprt a reliable estimate r rbust inference. Treatment plicy strategies might ffer the pssibility t btain a reliable estimate f a treatment effect that is still relevant. The resulting estimates shuld be presented alng with a discussin f the limitatins, in terms f trial design, data cllectin r statistical analysis. 56

136 Mdule Estimands Ntes abut the cmpsite strategy Rescue medicatin The treatment fails: patient cnsidered as nn-respnder N need t cllect data after use f rescue medicatin Example: select a binary variable. Respnse is based n a predefined threshld f change in scre in the absence f the intercurrent event. Patients wh experience the intercurrent event (rescue medicatin in this case) will be cnsidered nn-respnders. This dichtmisatin f cntinuus scres wuld result in a different variable, and thus a different estimand. 57

137 Mdule Estimands Ntes abut the hypthetical strategy Rescue medicatin N need t cllect the end pint value Part f patient time curse nt bserved and imputed/predicted Define the scientific questin f interest based n the effect if rescue medicatin had nt been available. The hypthetical cnditins described must therefre be justified fr the quantificatin f an interpretable treatment effect that is relevant t the use f the medicine in clinical practice. If the intercurrent event als depends n the reasn fr the event ccurring, bth event and reasn have t be defined mre precisely and recrded accurately in the clinical trial. 58

138 Mdule Estimands The experimental situatin shuld always be cnsidered! In particular, the chice f the cntrl arm might influence the manner in which rescue r ther cncmitant medicatins are permitted in the trial. 59

139 Next mdule: 2.4. Impact n trial design and cnduct Implicatins n design and cnduct f clinical trials and in the perfrmance f statistical analyses Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 60

140 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 2.4: Impact n trial design and cnduct Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

141 Mdule 2.4 Impact n trial design and cnduct Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

142 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule 2.4 Impact n trial design and cnduct This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

143 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule 2.4 Impact n trial design and cnduct These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

144 Mdule 2.4 Impact n trial design and cnduct Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

145 Mdule 2.4 Impact n trial design and cnduct ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin Mdule 2.1 A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.3 Mdule 2.2 6

146 Mdule 2.4 Impact n trial design and cnduct Outline f Mdule 2.4 ICH E9(R1) will have implicatins n hw we design and cnduct clinical trials and perfrm statistical analyses Identificatin f estimand(s) at the design stage requires infrmed discussin with all stakehlders Certain estimands may require r benefit frm nn-standard designs and/r endpints 7

147 Mdule 2.4 Impact n trial design and cnduct Impact n Trial Design The design f a trial needs t be aligned t the chice f the estimand r estimands that reflect the primary trial bjectives and which will frm the basis t establish whether thse bjectives have been met. ICH E6 lists imprtant aspects f trial design that shuld be stated in the prtcl. Alignment with the trial bjective and estimand shuld be sught when cnsidering, fr example: The type f trial (e.g., duble-blind, placeb-cntrlled, parallel design); Duratin f subject participatin, discntinuatin criteria fr individual subjects, subject withdrawal criteria, medicatins permitted befre and during the trial; Methds fr timing and assessing variables, prcedures fr mnitring subject cmpliance, specificatin f efficacy and/r safety parameters; The methds and timing fr assessing, recrding, and analysing efficacy and/r safety parameters. 8

148 Mdule 2.4 Impact n trial design and cnduct Impact n Data Cllectin The agreed estimand dictates the data that need t be cllected during the trial. Different estimands might have different requirements regarding data cllectin. Each trial is likely t have multiple estimands, which means that data cllectin shuld be determined by the need t address them all. The amunt f patient withdrawals frm the study desn t influence the relevance f a particular strategy r estimand, but the impact f ptential patient withdrawals n estimatin needs careful cnsideratin. 9

149 Mdule 2.4 Impact n trial design and cnduct Impact n Data Cllectin An estimand based n a treatment-plicy strategy requires the value fr the variable t be cllected fr all subjects regardless (i.e. befre and after) f the intercurrent event. Start f rescue medicatin Value at final time-pint cnsidered; Intercurrent event disregarded In cntrast, an estimand in which the variable is defined as a cmpsite f n use f rescue medicatin and a favurable clinical utcme des nt require cllectin f data after the use f rescue medicatin. Start f rescue medicatin Intercurrent event determines failure. N need t cllect value at the final time-pint Effrts shuld be made t cllect all data that are relevant t supprt a statistical analysis aligned t the estimands f interest. 10

150 Mdule 2.4 Impact n trial design and cnduct Design Optins Several nn-standard designs are available that can be aligned t the chice f the estimand r estimands that reflect the primary trial bjectives: Enrichment designs: incrprate a run-in perid in which a subset f the subjects are selected based n their likelihd f experiencing the intercurrent event f interest, e.g. the ppulatin f interest culd be patients wh tlerate the experimental treatment. Randmised withdrawal designs: all subjects are initially treated with the experimental treatment, then, subjects that have a psitive respnse t the experimental treatment are randmly selected either t remain n the experimental treatment r t be switched t placeb r alternative cntrl. Titratin designs: permit flexible dsing t accmmdate individual differences in drug respnse which may allw mre subjects t cntinue n the assigned treatment by reducing number f intercurrent events. Nt all types f design may be acceptable in all situatins. Apprpriate dialgues with regulatrs may be necessary. 11

151 Other imprtant aspects A precise descriptin f the estimand(s) f interest shuld infrm sample size calculatins. Fr summarising data acrss clinical trials, the same estimand shuld be cnsidered at the planning stage f the cntributing trials. Similar cnsideratins apply, fr example, t the design f a metaanalysis r the use f external cntrl grups fr the interpretatin f single-arm trials. A trial may have multiple bjectives translated int multiple estimands. ICH E9(R1) Step 2 Training Material Mdule 2.4 Impact n trial design and cnduct The multiplicity adjustments fr multiple endpints r multiple sub-grups can equally be applied t multiple estimands. 12

152 Next mdule: 2.5. Impact n trial analysis Rle and chice f sensitivity analysis and supplementary analysis in light f the estimand framewrk Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 13

153 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 2.5: Impact n trial analysis Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

154 Mdule 2.5 Impact n trial analysis Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

155 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule 2.5 Impact n trial analysis This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

156 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule 2.5 Impact n trial analysis These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

157 Mdule 2.5 Impact n trial analysis Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

158 Mdule 2.5 Impact n trial analysis ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin Mdule 2.1 A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.3 Mdule 2.2 6

159 Outline f Mdule 2.5 Main estimatin Sensitivity analysis Rle f sensitivity analysis Chice f sensitivity analysis Supplementary analysis ICH E9(R1) Step 2 Training Material Mdule 2.5 Impact n trial analysis 7

160 Mdule 2.5 Impact n trial analysis Main estimatin An analytic apprach, r estimatr, that is aligned with a given estimand shuld be implemented. Fr example, if addressing use f rescue medicatin with a treatment-plicy strategy; Analysis based n cntinued data cllectin after the intercurrent event and use f thse bserved data in the analysis wuld be aligned t the estimand, Nt attempting t cllect thse data and/r regarding data after rescue medicatin as missing then analysing thrugh MMRM with a MAR assumptin wuld nt be aligned t the estimand. Trial bjective Estimand Main estimatr Main estimate MMRM: Mixed Mdels fr Repeated Measures MAR: Missing At Randm 8

161 Mdule 2.5 Impact n trial analysis Main estimatin The estimatr selected shuld be able t prvide an estimate n which a reliable interpretatin can be based. An imprtant cnsideratin fr whether a reliable estimate will be available is the number and plausibility f assumptins that need t be made in the main analysis, including thse assciated with the use f mdelling t address missing data r t replace bserved data (as required fr estimatin in the hypthetical strategy). 9

162 Main estimatin ICH E9(R1) Step 2 Training Material Mdule 2.5 Impact n trial analysis Any assumptins made shuld be explicitly stated, and sensitivity analysis shuld be used t assess the rbustness f the results t the underlying assumptins. 10

163 Sensitivity analysis ICH E9(R1) Step 2 Training Material Mdule 2.5 Impact n trial analysis Sensitivity analysis Is a series f analyses targeting the same estimand, with differing assumptins t explre the rbustness f inferences frm the main estimatr t deviatins frm its underlying mdelling assumptins and limitatins in the data. Sensitivity analysis definitin, ICH E9(R1) Draft addendum 11

164 Mdule 2.5 Impact n trial analysis Main estimatin: missing data The addendum calls fr greater precisin n what is labelled as missing data. Assessments scheduled after an intercurrent event has ccurred (e.g. discntinuatin f treatment) shuld nt autmatically be set t missing: the relevance f these assessments will be determined by the strategy selected. Having clarity in the estimand gives a basis fr planning which data need t be cllected and hence which data, when nt cllected, present a missing data prblem t be addressed. 12

165 Missing data ICH E9(R1) Step 2 Training Material Mdule 2.5 Impact n trial analysis Missing data Data that wuld be meaningful fr the analysis f a given estimand but were nt cllected. They shuld be distinguished frm data that d nt exist r data that are nt cnsidered meaningful because f an intercurrent event. Missing data definitin, ICH E9(R1) Draft addendum 13

166 Mdule 2.5 Impact n trial analysis Check slides 28 and 34 f Mdule 2.3 Main estimatin: missing data Fr example: If planning t address the use f rescue medicatin with the treatmentplicy strategy, assessments scheduled after the use f rescue medicatin shuld cntinue as planned. Any assessments nt taken are missing data. If planning t address the use f rescue medicatin with a hypthetical strategy, assessments scheduled after the use f rescue medicatin might nt be required fr estimatin. Methds t address the prblem presented by missing data can be selected t align with the chsen estimand. 14

167 Mdule 2.5 Impact n trial analysis Rle f sensitivity analysis Sensitivity analysis is used t evaluate the rbustness f inferences made n a particular estimand t limitatins in the data and deviatins frm the assumptins used in the statistical mdel fr the main estimatr. With an agreed estimand, and a pre-specified statistical analysis that is aligned t that estimand, sensitivity analysis can fcus n sensitivity t deviatins frm assumptins in respect f a particular analysis rather than sensitivity t the chice f analytic apprach. 15

168 Mdule 2.5 Impact n trial analysis Rle f sensitivity analysis In general, the statistical assumptins that underpin the main estimatr shuld be clearly dcumented. One r mre analyses, fcused n the same estimand, shuld then be pre-specified t investigate the impact f deviatins frm these assumptins. Missing data require particular attentin in a sensitivity analysis because the assumptins underlying any methd may be hard t justify fully and may be impssible t test. 16

169 Mdule 2.5 Impact n trial analysis Supplementary analysis If the estimate crrespnding t a given estimatr, and assciated inference, is shwn t be rbust thrugh sensitivity analysis, then the interpretatin f trial results shuld fcus n the main estimatr fr each selected estimand. Any ther analysis that is planned, presented r requested in rder t mre fully investigate and understand the trial data and the effects f treatment is referred t as a supplementary analysis. Supplementary analysis might target different estimands, r target the same estimand based n a different analytical apprach. 17

170 Mdule 2.5 Impact n trial analysis Supplementary analysis Supplementary analysis Is a general descriptin fr analyses that are cnducted in additin t the main and sensitivity analysis t prvide additinal insights int the understanding f the treatment effect. The term describes a brader class f analyses than sensitivity analyses. Supplementary analysis definitin, ICH E9(R1) Draft addendum 18

171 Mdule 2.5 Impact n trial analysis Supplementary analysis Supplementary analysis shuld be clearly distinguished frm sensitivity analysis, and in general, shuld be given a lwer pririty relative t a sensitivity analysis. Fr example, investigating assumptins f nrmality assciated with ANOVA wuld result in sensitivity analysis; analysing the dataset instead based n cmparisn f medians wuld be cnsidered a supplementary analysis. ANOVA: Analysis f variance 19

172 Next mdule: 2.6. Dcumenting estimands and sensitivity analysis Impact f the addendum n prtcl writing, study design, data analysis and interpretatin Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 20

173 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 2.6: Dcumenting estimands and sensitivity analysis Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

174 Mdule Dcumenting estimands and sensitivity analysis Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

175 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule Dcumenting estimands and sensitivity analysis This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

176 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule Dcumenting estimands and sensitivity analysis These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

177 Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example ICH E9(R1) Step 2 Training Material Mdule Dcumenting estimands and sensitivity analysis 5

178 ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin Mdule 2.1 A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary ICH E9(R1) Step 2 Training Material Mdule Dcumenting estimands and sensitivity analysis Mdule 2.5 Mdule 2.6 Mdule 2.3 Mdule 2.2 6

179 Mdule Dcumenting estimands and sensitivity analysis Outline f Mdule 2.6 Incrprating estimands in the writing f a trial prtcl and statistical analysis plan Ptential impact f ICH E9(R1) n study cnduct Data analysis and interpretatin 7

180 Mdule Dcumenting estimands and sensitivity analysis Incrprating estimands in prtcl writing Clinical Trial Trial Prtcl Estimands shuld be defined and explicitly specified in the clinical trial prtcl. The primary estimand pre-specified in the trial prtcl shuld crrespnd t the primary trial bjective. The prtcl and the statistical analysis plan shuld pre-specify the main estimatr that is aligned with the primary estimand and leads t the primary analysis. Suitable sensitivity analysis shuld be planned t explre the rbustness under deviatins frm its assumptins. 8

181 Mdule Dcumenting estimands and sensitivity analysis Incrprating estimands in prtcl writing Clinical Trial Trial Prtcl Estimands fr secndary trial bjectives (e.g. related t secndary variables) that are likely t supprt regulatry decisins shuld be described prperly, each with a crrespnding main estimatr. Suitable sensitivity analysis shuld be planned. Additinal trial bjectives may be cnsidered fr explratry purpses, leading t additinal estimands. It is nt a regulatry requirement t dcument in detail an estimand fr each explratry questin. 9

182 Mdule Dcumenting estimands and sensitivity analysis Incrprating estimands in prtcl writing Clinical Trial Trial Prtcl Where different scientific questins f interest call fr materially different estimands, it is recmmended that these shuld be fully dcumented. The chice f the primary estimand will usually be the main determinant fr aspects f trial design. 10

183 Mdule Dcumenting estimands and sensitivity analysis Incrprating estimands in prtcl writing The trial analysis summarised in the prtcl shuld be aligned with the primary estimand with regards t (including but nt limited t): Handling f intercurrent events, fr example: - Use f rescue medicatin; - Changes in permitted medicatins; - Switching treatments; - Discntinuing treatment; - Subject deaths. The selectin f subjects t be included in the analyses. Multiplicity issues e.g. if there is mre than ne estimand. 11

184 Mdule Dcumenting estimands and sensitivity analysis Incrprating estimands in prtcl writing Clinical Trial Trial Prtcl ICH E9(R1) des nt mandate where in the prtcl estimands shuld be described, nr mandate hw estimands shuld be described. 12

185 Mdule Dcumenting estimands and sensitivity analysis Incrprating estimands in the SAP Clinical Trial Trial Prtcl Statistical Analysis Plan Full details f the planned statistical analyses shuld align with the estimand(s) defined, and nt the ther way arund! SAP: Statistical Analysis Plan 13

186 Mdule Dcumenting estimands and sensitivity analysis Ptential impact n study cnduct Clinical Trial The ccurrence f anticipated intercurrent events shuld be mnitred during the study. Estimands defined in the trial prtcl culd be subsequently affected by issues arising during study cnduct. The impact f any unanticipated intercurrent events ccurring and/r ther study cnduct issues pssibly affecting the primary estimand shuld be evaluated. A prtcl amendment culd be cnsidered depending n the nature and significance f such issues t the primary estimand. 14

187 Mdule Dcumenting estimands and sensitivity analysis Data analysis and interpretatin Clinical Trial Results frm the main, sensitivity and any supplementary analyses shuld be reprted systematically in the clinical trial reprt, specifying whether each analysis was pre-specified, intrduced while the trial was still blinded, r perfrmed pst hc. 15

188 Mdule Dcumenting estimands and sensitivity analysis Data analysis and interpretatin Clinical Trial Fr intercurrent events that were nt freseen at the design stage, and were identified during the cnduct f the trial with n pssibility t frmally amend the estimand specified in the prtcl, the spnsr shuld: explain hw the unfreseen intercurrent events were handled in the analysis; explain the impact n what the revised analysis estimates (i.e. the impact n the pre-specified estimand). Cnsultatin with regulatrs t agree the preferred handling f intercurrent events nt initially freseen might be advisable. 16

189 Next mdule: 3. Generic example Internatinal Cnference n Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 17

190 Draft (Step 2) guideline ICH E9(R1) Estimands and Sensitivity Analysis in Clinical Trials Training mdule 3: Generic Example Addendum t ICH E9 Statistical Principles fr Clinical Trials ICH E9(R1) Expert Wrking Grup June 2018 Internatinal Cuncil fr Harmnisatin f Technical Requirements fr Registratin f Pharmaceuticals fr Human Use 1

191 Mdule 3 Generic example Disclaimer This presentatin includes the authrs views n thery and practice regarding estimands and sensitivity analysis in clinical trials. The presentatin des nt represent fficial guidance r plicy f authrities r industry and it des nt prvide additinal guidance beynd ICH E9(R1). The current slide deck reflects the cntent n the Draft ICH E9(R1) addendum up t the time f its publicatin fr public cnsultatin. Cntent may be changed as a result f the cnsultatin phase. 2

192 Legal Ntice ICH E9(R1) Step 2 Training Material Mdule 3 Generic example This presentatin is prtected by cpyright and may be used, reprduced, incrprated int ther wrks, adapted, mdified, translated r distributed under a public license prvided that ICH's cpyright in the presentatin is acknwledged at all times. In case f any adaptatin, mdificatin r translatin f the presentatin, reasnable steps must be taken t clearly label, demarcate r therwise identify that changes were made t r based n the riginal presentatin. Any impressin that the adaptin, mdificatin r translatin f the riginal presentatin is endrsed r spnsred by the ICH must be avided. The presentatin is prvided "as is" withut warranty f any kind. In n event shall the ICH r the authrs f the riginal presentatin be liable fr any claim, damages r ther liability arising frm the use f the presentatin. The abve-mentined permissins d nt apply t cntent supplied by third parties. Therefre, fr dcuments where the cpyright vests in a third party, permissin fr reprductin must be btained frm this cpyright hlder. 3

193 Intrductin nte ICH E9(R1) Step 2 Training Material Mdule 3 Generic example These slides were prduced as training material t accmpany the Draft ICH E9(R1) addendum. The intentin is t supprt the scientific cmmunity in the cmprehensin f a new framewrk t define estimands based n the trial bjective and cnsidering intercurrent events. Fr this purpse, mst f the cntent f this addendum is presented in a practical fashin, accmpanied by examples and case studies dealing with estimands and sensitivity analysis in clinical trials, based n the experience f Expert Wrking Grup members. The training material is divided in three main mdules: mdule 1 (summary), mdule 2 (cmprehensive slide deck) and mdule 3 (generic example). Mdule 2 is cmpsed by 6 submdules that crrespnd t sectins A.1 t A.6 f the addendum. 4

194 Mdule 3 Generic example Training mdules Mdule 1: Summary Mdule 2: Cmprehensive slide deck Mdule 2.1: Intrductin Mdule 2.2: Framewrk Mdule 2.3: Estimands Mdule 2.4: Impact n trial design and cnduct Mdule 2.5: Impact n trial analysis Mdule 2.6: Dcumenting estimands and sensitivity analysis Mdule 3: Generic example 5

195 ICH E9(R1) Table f Cntents A.1. Purpse and Scpe A.2. A Framewrk t Align Planning, Design, Cnduct, Analysis and Interpretatin A.3. Estimands A.3.1. Descriptin A.3.2. Strategies fr Addressing Intercurrent Events A.3.3. Cnstructin f Estimands - A General Cnsideratins - A Cnsideratins f Therapeutic and Experimental Cntext A.4. Impact n Trial Design and Cnduct Mdule 2.4 A.5. Impact n Trial Analysis A.5.1. Main Estimatin A.5.2. Sensitivity Analysis - A Rle f Sensitivity Analysis - A Chice f Sensitivity Analysis A.5.3. Supplementary Analysis ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Mdule 2.1 A.6. Dcumenting Estimands and Sensitivity Analysis A.7. A Generic Example A.7.1. One Intercurrent Event Mdule 3 A.7.2. Tw Intercurrent Events Glssary Mdule 2.5 Mdule 2.6 Mdule 2.3 Mdule 2.2 6

196 Estimands and Sensitivity Analysis A thinking prcess 7

197 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 8

198 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 9

199 Mdule 3 Generic example Check Mdule Therapeutic setting and intent f treatment determining a trial bjective The therapeutic setting and the intent f treatment will determine the trial bjective. An understanding f the therapeutic setting includes the disease r cnditin under study and, fr example, the availability f ther treatment ptins and the pssibilities t mnitr individual respnse t treatment. Diagnsis, treatment and preventin are different intents f treatment and will determine different trial bjectives. Tgether these will start t shape the estimand attributes (Mdule 2.3). Check Mdule

200 Mdule 3 Generic example 1 Therapeutic setting and intent f treatment determining a trial bjective Example Drug X Fr example, a treatment might be intended fr a chrnic nn-life-threatening cnditin. The develpment prgramme might aim t investigate the effect f treatment t cntrl a sign r symptm f the disease. This will give rise t initial thughts fr the target ppulatin and the variable. Fr the example, cnsider a variable measured mnthly n a cntinuus scale (e.g. systlic bld pressure, SBP, after 6 mnths in hypertensin). SBP: Systlic bld pressure 11

201 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 12

202 Mdule 3 Generic example Check Mdule Identify intercurrent events Intercurrent events Events that ccur after treatment initiatin and either preclude bservatin f the variable r affect its interpretatin. Intercurrent events definitin, ICH E9(R1) Draft addendum These events (e.g. death) that preclude the bservatin f the variable, shuld nt be cnfused with missing data resulting frm lss t fllw-up that can ccur in a clinical trial 13

203 Mdule 3 Generic example Check Mdule Identify intercurrent events Cmmn intercurrent events Treatment discntinuatin/nn-adherence t treatment, perhaps identified as multiple separate intercurrent events distinguished by reasn (e.g. treatment discntinuatin due t lack f efficacy, due t txicity, ); Use f additinal medicatin, perhaps distinguished by type and / r reasn, e.g.: - rescue medicatin due t lack f efficacy; treatment switch; use f prhibited medicatin; change in backgrund medicatin; Death and ther terminal events. Address each intercurrent event that will affect the interpretatin f the trial results, nt nly the mst frequently ccurring 14

204 Mdule 3 Generic example 2 Identify intercurrent events Examples f intercurrent events that might be freseen 1. Treatment discntinuatin/nn-adherence t treatment. 2. Use f additinal medicatin (that will impact measurements f SBP). Example Drug X SBP: Systlic bld pressure 15

205 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 16

206 Mdule 3 Generic example Check Mdule Discuss strategies t address intercurrent events Discuss Cnsider different strategies t address these tw intercurrent events (slides and respectively). Reflect hw t accunt fr intercurrent events thrugh the estimand attributes A-D (see Mdule 2.3, illustrated n the fllwing slides). 17

207 Mdule 3 Generic example Check Mdule Discuss strategies t address intercurrent events Chse each strategy t reflect the scientific questin f interest. Each chice f strategy shuld be driven by the trial bjective and nt by the preferred chice f estimatr. Cnsider: Is what is t be estimated relevant fr spnsr, regulatr and prescriber decisin making? Can an estimate that is reliable fr inference be btained? The chice f strategy fr each intercurrent event shuld be the subject f multi-disciplinary discussin within the spnsr s team, within the regulatr s team and between spnsr and regulatr. 18

208 Mdule 3 Generic example 3 Discuss strategies t address intercurrent events Cnsider the pssible strategies t address each intercurrent event Objective = quantifying the effects f treatment n SBP. Intercurrent event (1) = treatment discntinuatin. Cnsider different strategies: Example Drug X 1. Treatment plicy: t investigate a treatment effect at mnth 6 regardless f whether r nt the patients cntinue with treatment (specified in attribute C). SBP: Systlic bld pressure 19

209 Mdule 3 Generic example 3 Discuss strategies t address intercurrent events Example Drug X 2. Cmpsite: fr example, the treatment effect is established based n a cmpsite variable cmbining a clinically meaningful change in SBP and cntinuatin f treatment at mnth 6. Thus bth lack f meaningful change and treatment discntinuatin will be captured as unfavurable utcmes (specified, if using a cmpsite variable, in attribute B). 3. Hypthetical: t investigate a treatment effect at mnth 6 if all patients cntinue with treatment (specified in attribute C). SBP: Systlic bld pressure 20

210 Mdule 3 Generic example 3 Discuss strategies t address intercurrent events Example Drug X 4. Principal stratum: t investigate the effect f treatment at mnth 6 in the stratum f the ppulatin wh wuld be able t cntinue treatment with drug X (specified in attribute A). 5. While n treatment: t investigate the effect f treatment while the patient cntinues t take their treatment rather than at a fixed time (i.e. 6 mnths) after initiatin f treatment (specified in attribute B). 21

211 Mdule 3 Generic example 3 Discuss strategies t address intercurrent events Cnsider the pssible strategies t address each intercurrent event Objective = quantifying the effects f the treatment n SBP. Intercurrent event (2) = use f additinal medicatin that affects SBP. Cnsider different strategies: Example Drug X 1. Treatment plicy: investigate the treatment effect at mnth 6 regardless f whether r nt the patient uses additinal medicatin. This strategy will capture bth the effect f Drug X and the effect f additinal medicatin (specified in attribute C). SBP: Systlic bld pressure 22

212 Mdule 3 Generic example 3 Discuss strategies t address intercurrent events Example Drug X 2. Cmpsite: fr example, the treatment effect is established based n a cmpsite variable indicating a clinically meaningful change btained withut the use f additinal medicatin at mnth 6. This will capture bth lack f meaningful change and the use f additinal medicatin as unfavurable utcmes (specified, if using a cmpsite variable, in attribute B). 3. Hypthetical: investigate the treatment effect at mnth 6 if additinal medicatin wuld nt be available t patients. This strategy aims t capture the effect f drug X withut the effect f additinal medicatin (specified in attribute C). 23

213 Mdule 3 Generic example 3 Discuss strategies t address intercurrent events Example Drug X 4. Principal stratum: t investigate the effect f treatment at mnth 6 in the stratum f the ppulatin wh wuld nt use additinal medicatin n drug X (specified in attribute A). 5. While n treatment: t investigate the effect f treatment befre the pint at which the patient uses additinal medicatin (specified in attribute B). 24

214 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 25

215 Mdule 3 Generic example 4 Cnstruct the estimand(s) Example Drug X Select a preferred strategy fr each intercurrent event: Fr illustratin* we chse: Treatment discntinuatin/nn-adherence t treatment Treatment plicy (specified in attribute C). Use f additinal r alternative medicatin that affects SBP Hypthetical (specified in attribute C). * This is nt an indicatin f regulatry preference r plicy SBP: Systlic bld pressure 26

216 Mdule 3 Generic example 4 Cnstruct the estimand(s) Definitin f the estimand (4 attributes): A. Ppulatin: defined thrugh apprpriate inclusin/exclusin criteria t reflect the targeted patient ppulatin fr apprval. B. Endpint: change frm baseline t mnth 6 in SBP. Example Drug X C. Hw t accunt fr intercurrent events: if additinal medicatin was nt available t patients prir t mnth 6 and regardless f whether r nt the patient cntinue with treatment D. Ppulatin-level summary: difference in variable means between treatment cnditins. SBP: Systlic bld pressure 27

217 Mdule 3 Generic example 4 Cnstruct the estimand(s) A descriptin f the estimand might be*: Example Drug X The difference in means between treatment cnditins in the target patient ppulatin fr the change frm baseline t mnth 6 in SBP, if additinal medicatin was nt available t patients prir t mnth 6 and regardless f whether r nt the patient cntinues with treatment. * This is nt an indicatin f regulatry preference r plicy SBP: Systlic bld pressure 28

218 Mdule 3 Generic example 4 Cnstruct the estimand(s) Select a preferred strategy fr each intercurrent event: As a secnd illustratin* we chse: Example Drug X Treatment discntinuatin/nn-adherence t treatment Treatment plicy (specified in attribute C). Use f additinal r alternative medicatin that affects SBP Cmpsite (specified in attribute B). * This is nt an indicatin f regulatry preference r plicy SBP: Systlic bld pressure 29

219 Mdule 3 Generic example 4 Cnstruct the estimand(s) Definitin f the secnd estimand (4 attributes): Example Drug X A. Ppulatin: defined thrugh apprpriate inclusin/exclusin criteria t reflect the targeted patient ppulatin fr apprval. B. Endpint: binary respnse variable indicating a successful respnse if a clinically meaningful change frm baseline t mnth 6 in SBP is btained withut the use f additinal medicatin C. Hw t accunt fr intercurrent events: regardless f whether r nt the patient cntinue with treatment. D. Ppulatin-level summary: difference in respnse prprtins between treatment cnditins. SBP: Systlic bld pressure 30

220 Mdule 3 Generic example 4 Cnstruct the estimand(s) A descriptin f the estimand might be*: Example Drug X The difference in respnse prprtins between treatment cnditins in the target patient ppulatin in successful respnses at mnth 6 in SBP withut use f additinal medicatin, regardless f whether r nt the patient cntinues with treatment. * This is nt an indicatin f regulatry preference r plicy SBP: Systlic bld pressure 31

221 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 32

222 Mdule 3 Generic example Check Mdule Align chices n trial design, data cllectin and methd f estimatin In additin t chsing strategies t reflect the scientific questin f interest, it is necessary t determine that an apprpriate trial design and statistical analysis can be perfrmed. Specifically: Cnsider the data that need t be cllected. - Difficulties in data cllectin fllwing the ccurrence f an intercurrent event are nt necessarily a strng ratinale t change an estimand r strategy Cnsider whether an estimate f treatment effect can be derived that is reliable fr decisin making. 33

223 Mdule 3 Generic example Check Mdule Align chices n trial design, data cllectin and methd f estimatin A balance might need t be struck between an estimand f greater clinical relevance estimated with an analytical apprach that requires numerus assumptins, and an estimand f less clinical relevance that can be estimated with an analytical apprach requiring few assumptins. This will depend n the extent t which sensitivity analysis can prvide cnfidence in the reliability f the results. 34

224 Mdule 3 Generic example 5 Align chices n trial design, data cllectin and methd f estimatin Example Drug X A randmised cntrlled trial cmparing Drug X t placeb is cnsidered the mst apprpriate design t investigate the research questin. Cnsider the data that wuld need t be cllected, e.g. fr the use f additinal medicatin: fr a treatment-plicy strategy it shuld be planned that all measurements f SBP regardless f use f additinal medicatin are cllected thrughut the trial; fr a hypthetical strategy measurements f SBP after the use f additinal medicatin wuld nt need t be cllected (fr this estimand, but might be required fr thers). SBP: Systlic bld pressure 35

225 Mdule 3 Generic example 5 Align chices n trial design, data cllectin and methd f estimatin Example Drug X Cnsider whether an estimate f treatment effect can be derived that is reliable fr decisin making, e.g. fr the use f additinal medicatin: fr a treatment-plicy strategy if all data are cllected then analysis might rely n few assumptins. Otherwise, estimatin will rely n mdel assumptins that require extensive sensitivity analysis. fr a hypthetical strategy measurements f SBP after the use f additinal medicatin are nt relevant and values must be imputed r predicted, relying n mdel assumptins that require mre extensive sensitivity analysis. SBP: Systlic bld pressure 36

226 Mdule 3 Generic example 5 Align chices n trial design, data cllectin and methd f estimatin Example Drug X Cnsider whether an estimate f treatment effect can be derived that is reliable fr decisin making, e.g. fr the use f additinal medicatin (cntinued): fr a principal stratum strategy estimatin f a treatment effect will be cnfunded unless the subjects within that stratum can be identified befre randmisatin. Otherwise, estimatin will rely n mdel assumptins that will require extensive sensitivity analysis. fr a while n treatment strategy estimatin f a treatment effect will require strng assumptins when the ccurrence and timing f an intercurrent event is related t treatment and will require extensive sensitivity analysis. The extent f sensitivity analysis required in estimatin might preclude the chice f a particular estimand. 37

227 Mdule 3 Generic example 5 Align chices n trial design, data cllectin and methd f estimatin Estimand* (slide 28): The difference in means between treatment cnditins in the target patient ppulatin fr the change frm baseline t mnth 6 in SBP, if additinal medicatin was nt available t patients prir t mnth 6 and regardless f whether r nt the patient cntinues with treatment. Discuss and select a methd fr estimatin* that is aligned t the estimand: Example Drug X e.g. ANCOVA with imputatin f the measurements after the patient uses additinal medicatin, perhaps based n data in the placeb grup. SBP: Systlic bld pressure ANCOVA: Analysis f cvariance * This is nt an indicatin f regulatry preference r plicy 38

228 A thinking prcess ICH E9(R1) Step 2 Training Material Mdule 3 Generic example Therapeutic setting and intent f treatment determining a trial bjective Identify intercurrent events Discuss strategies t address intercurrent events Cnstruct the estimand(s) Align chices n trial design, data cllectin and methd f estimatin Identify assumptins fr the main analysis and suitable sensitivity analyses t investigate these assumptins 7 Dcument the chsen estimands 39

229 Mdule 3 Generic example Check Mdule Identify assumptins fr the main analysis and suitable sensitivity analysis t investigate these assumptins Sensitivity analysis Is a series f analyses targeting the same estimand, with differing assumptins t explre the rbustness f inferences frm the main estimatr t deviatins frm its underlying mdelling assumptins and limitatins in the data. Sensitivity analysis definitin, ICH E9(R1) Draft addendum Assumptins made by the analytical apprach must be investigated thrugh apprpriate sensitivity analysis. Analyses cnducted fr reasns ther than t investigate the assumptins made by the main analysis are supplementary analysis. 40

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information

Structured Assessment using Multiple Patient. Scenarios (StAMPS) Exam Information Structured Assessment using Multiple Patient Scenaris (StAMPS) Exam Infrmatin 1. Preparing fr the StAMPS assessment prcess StAMPS is an assessment mdality that is designed t test higher rder functins in

More information

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams

Assessment Field Activity Collaborative Assessment, Planning, and Support: Safety and Risk in Teams Assessment Field Activity Cllabrative Assessment, Planning, and Supprt: Safety and Risk in Teams OBSERVATION Identify a case fr which a team meeting t discuss safety and/r safety planning is needed r scheduled.

More information

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS

EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS 1 SECTION 1 INTRODUCTION: EXPLORING THE PROCESS OF ASSESSMENT AND OTHER RELATED CONCEPTS The Nature Of Assessment The Definitin Of Assessment The Difference Between Testing, Measurement And Evaluatin Characteristics

More information

Programme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport

Programme of Learning. Physical Education. Key Stage 4 Year 10 BTEC Sport Prgramme f Learning Physical Educatin Key Stage 4 Year 10 BTEC Sprt BTEC Sprt Level 2 Unit 1Fitness fr Sprt and Exercise... 2 Learning aim A: Knw abut the cmpnents f fitness and the principles f training...

More information

Strategic Plan Publication No: EO-SP

Strategic Plan Publication No: EO-SP Strategic Plan 2017-2019 Publicatin N: EO-SP-170223 +61 2 9036 5002 www.pcg.rg.au pcg.ffice@sydney.edu.au This dcument was prepared by the PCG Executive Office PCG Publicatin number: EO-SP-170223 Psych-nclgy

More information

2018 Medical Association Poster Symposium Guidelines

2018 Medical Association Poster Symposium Guidelines 2018 Medical Assciatin Pster Sympsium Guidelines Overview The 3 rd Annual student-run Medical Assciatin f the State f Alabama Research Sympsium will take place n Friday and Saturday, April 13-14 at the

More information

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps.

A pre-conference should include the following: an introduction, a discussion based on the review of lesson materials, and a summary of next steps. NAU Mdel Observatin Prtcl The mdel prtcl was develped with supprt and expertise frm the Natinal Institute fr Excellence in Teaching (NIET) and is based in great part n NIET s extensive experience cnducting

More information

Corporate Governance Code for Funds: What Will it Mean?

Corporate Governance Code for Funds: What Will it Mean? Crprate Gvernance Cde fr Funds: What Will it Mean? The Irish Funds Industry Assciatin has circulated a draft Vluntary Crprate Gvernance Cde fr the Funds Industry in Ireland. 1. Backgrund On 13 June 2011,

More information

Code of employment practice on infant feeding

Code of employment practice on infant feeding Cde f emplyment practice n infant feeding An Emplyer s guide t: Sectin 69Y f the Emplyment Relatins Act 2000 Frewrd As Minister f Labur, I am pleased t publish the Cde f Emplyment Practice n Infant Feeding.

More information

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017

P02-03 CALA Program Description Proficiency Testing Policy for Accreditation Revision 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin Revisin 1.9 July 26, 2017 P02-03 CALA Prgram Descriptin Prficiency Testing Plicy fr Accreditatin TABLE OF CONTENTS TABLE OF CONTENTS...

More information

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH

GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH GUIDANCE DOCUMENT FOR ENROLLING SUBJECTS WHO DO NOT SPEAK ENGLISH Aurra Health Care s Research Subject Prtectin Prgram (RSPP) This guidance dcument will utline the prper prcedures fr btaining and dcumenting

More information

Commissioning Policy: South Warwickshire CCG (SWCCG)

Commissioning Policy: South Warwickshire CCG (SWCCG) Cmmissining Plicy: Suth Warwickshire CCG (SWCCG) Treatment Indicatin Criteria FreeStyle Libre Flash Cntinuus Glucse Mnitring System Type I Diabetes Prir apprval must be requested frm the Individual Funding

More information

EDPS 475: Instructional Objectives for Midterm Exam Behaviorism

EDPS 475: Instructional Objectives for Midterm Exam Behaviorism EDPS 475: Instructinal Objectives fr Midterm Exam Behavirism 1. Given a nvel example t chse frm, identify the characteristics f classical cnditining. General mdel: Stimulus (S) elicits >Respnse (R) Based

More information

Cardiac Rehabilitation Services

Cardiac Rehabilitation Services Dcumentatin Guidance N. DG1011 Cardiac Rehabilitatin Services Revisin Letter A 1.0 Purpse The Centers fr Medicare and Medicaid Services (CMS) has detailed specific dcumentatin requirements fr Cardiac Rehabilitatin

More information

Success Criteria: Extend your thinking:

Success Criteria: Extend your thinking: Discussin Directr Yur jb is t invlve thers in cnversatin abut the text by getting them t think and talk abut the BIG IDEAS in the chapter/ sectin they have just read. Cmpse 5 questins that yu want t discuss

More information

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.

This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. abcd Clinical Study Synpsis fr Public Disclsure This clinical study synpsis is prvided in line with Behringer Ingelheim s Plicy n Transparency and Publicatin f Clinical Study Data. The synpsis which is

More information

The principles of evidence-based medicine

The principles of evidence-based medicine The principles f evidence-based medicine By the end f this mdule yu shuld be able t: Describe what evidence based medicine is Knw where t find quality evidenced based medicine n the internet Be able t

More information

Herbal Medicines: Traditional Herbal Registration

Herbal Medicines: Traditional Herbal Registration Herbal Medicines: Traditinal Herbal Registratin In the UK, cmpanies can nly sell herbal medicines with the apprpriate prduct licence, as fllws: A full marketing authrisatin based n the safety, quality

More information

Reliability and Validity Plan 2017

Reliability and Validity Plan 2017 Reliability and Validity Plan 2017 Frm CAEP The principles fr measures used in the CAEP accreditatin prcess include: (a) validity and reliability, (b) relevance, (c) verifiability, (d) representativeness,

More information

Methadone Maintenance Treatment for Opioid Dependence

Methadone Maintenance Treatment for Opioid Dependence POLICY STATEMENT Methadne Maintenance Treatment fr Opiid Dependence APPROVED BY COUNCIL: May 2010 PUBLICATION DATE: Dialgue, Issue 2, 2010 Disclaimer: As f May 19, 2018 physicians n lnger require an exemptin

More information

Module 6: Goal Setting

Module 6: Goal Setting Mdule 6: Gal Setting Objectives T understand the cncept f gal setting in Brief CBT T acquire skills t set feasible and apprpriate gals in Brief CBT What is gal setting, and why is it imprtant t set gals

More information

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION

EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION EXECUTIVE SUMMARY INNOVATION IS THE KEY TO CHANGING THE PARADIGM FOR THE TREATMENT OF PAIN AND ADDICTION TO CREATE AN AMERICA FREE OF OPIOID ADDICTION The Bitechnlgy Innvatin Organizatin (BIO) and ur member

More information

TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT

TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT TELCOMMUNICATIONS CONSUMER PROTECTIONS CODE (C628:2012) EXPLANATORY STATEMENT Intrductin This is the Explanatry Statement fr the revised Cmmunicatins Alliance Telecmmunicatins Cnsumer Prtectins (TCP) Industry

More information

Annual Principal Investigator Worksheet About Local Context

Annual Principal Investigator Worksheet About Local Context Cmpleting the NCI CIRB Annual Principal Investigatr Wrksheet Abut Lcal Cntext and the Study-Specific Wrksheet Abut Lcal Cntext at the University f Iwa All investigatrs cnducting research with the Natinal

More information

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION

CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION CONSENT FOR KYBELLA INJECTABLE FAT REDUCTION INSTRUCTIONS This is an infrmed cnsent dcument which has been prepared t help yur Dctr infrm yu cncerning fat reductin with an injectable medicatin, its risks,

More information

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking

Public consultation on the NHMRC s draft revised Australian alcohol guidelines for low-risk drinking Public cnsultatin n the NHMRC s draft revised Australian alchl guidelines fr lw-risk drinking Recmmendatins frm The Cancer Cuncil Australia The Cancer Cuncil Australia is Australia s peak nn-gvernment

More information

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals.

ACSQHC National Consensus Statement: Essential Elements for High Quality End-oflife Care in Acute Hospitals. 27 March 2014 Prfessr Debra Picne Chief Executive Officer Australian Cmmissin n Safety and Quality in Health Care c/ Ms Jennifer Hill, Senir Prject Officer Level 5, 255 Elizabeth Street SYDNEY NSW 2000

More information

Chapter 6: Impact Indicators

Chapter 6: Impact Indicators Overview Chapter 6: Impact Indicatrs The best measure f the lng-term impact f all HIV preventin activities is the HIV incidence rate, namely the number f new cases f HIV infectin per year divided by the

More information

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS

DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 2016 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS DATA RELEASE: UPDATED PRELIMINARY ANALYSIS ON 216 HEALTH & LIFESTYLE SURVEY ELECTRONIC CIGARETTE QUESTIONS This briefing has been specifically prepared fr the Ministry f Health t prvide infrmatin frm this

More information

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only. The clinical trial infrmatin prvided in this public disclsure synpsis is supplied fr infrmatinal purpses nly. Please nte that the results reprted in any single trial may nt reflect the verall ptential

More information

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST

LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST OPTUM LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY / APPLIED BEHAVIOR ANALYSIS FOR AUTISM SPECTRUM DISORDER HAWAII MEDICAID QUEST LEVEL OF CARE GUIDELINES: INTENSIVE BEHAVIORAL THERAPY/APPLIED

More information

Lesson Unit content* Activities Resource checklist Links to other units

Lesson Unit content* Activities Resource checklist Links to other units BTEC First Sprt Unit 1: Fitness fr Sprt and Exercise Scheme f wrk Guided learning hurs (GLH): 30 Number f lessns: 20 Duratin f lessns: 1-2 hurs (as shwn) This scheme f wrk is prvided t help yu make the

More information

REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES

REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES REGISTERED REPORTS AUTHOR AND REVIEWER GUIDELINES A Registered Reprt is a frm f empirical article ffered at Nature Human Behaviur in which the methds and prpsed analyses are pre-registered and reviewed

More information

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA

Assessment criteria for Primary Health Disciplines Eligibility for Recognition as Credentialled Diabetes Educator. December 2015 ADEA Assessment criteria fr Primary Health Disciplines Eligibility fr Recgnitin as Credentialled Diabetes Educatr December 2015 ADEA ASSESSMENT CRITERIA FOR PRIMARY HEALTH DICIPLINES ELIGIBILITY FOR RECOGNITION

More information

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain

Pennsylvania Guidelines on the Use of Opioids to Treat Chronic Noncancer Pain Pennsylvania Guidelines n the Use f Opiids t Treat Chrnic Nncancer Pain Chrnic pain is a majr health prblem in the United States, ccurring with a pintprevalence f abut ne-third f the US ppulatin.(1) Mre

More information

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations

Implementation of G6PD testing and radical cure in P. vivax endemic countries: considerations Implementatin f G6PD testing and radical cure in P. vivax endemic cuntries: cnsideratins Malaria Plicy Advisry Cmmittee Geneva, Switzerland 16-18 September 2015 1 WHO Guidelines n Radical Cure WHO guidelines

More information

Proposal 101: So, You Want to Change the World AND Receive Funding to do so?

Proposal 101: So, You Want to Change the World AND Receive Funding to do so? Prpsal 101: S, Yu Want t Change the Wrld AND Receive Funding t d s? Pamela Mitzelfeld Sherry Wynn Perdue Oakland University Writing Center 212 Kresge Library The Nature f Prpsals There is n such thing

More information

Swindon Joint Strategic Needs Assessment Bulletin

Swindon Joint Strategic Needs Assessment Bulletin Swindn Jint Strategic Needs Assessment Bulletin Swindn Diabetes 2017 Key Pints: This JSNA gives health facts abut peple with diabetes r peple wh might get diabetes in Swindn. This helps us t plan fr medical

More information

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator

British Sign Language (BSL) Plan October 2018 Scottish Charity Regulator British Sign Language (BSL) Plan 2018-2024 Octber 2018 Scttish Charity Regulatr Cntents Sectin 1: Intrductin and cntext 1.1 Intrductin 1.2 Our wrk and what we d Sectin 2: Our BSL Plan 2.1 Scttish Public

More information

Code of Conduct for Employees

Code of Conduct for Employees Crprate Human Resurces Plicy Cntent Updated: 2016-06-22 Wrk Envirnment Plicy N: HR-01-09 Page 1 f 5 Apprval: 2014-09-24 Cde f Cnduct fr Emplyees POLICY STATEMENT The residents and businesses f the City

More information

Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of depression

Concept paper on the need for revision of the guideline on clinical investigation of medicinal products in the treatment of depression 1 2 3 10 Nvember 2016 EMA/CHMP/183826/2016 Cmmittee fr Medicinal Prducts fr Human Use (CHMP) 4 5 6 7 Cncept paper n the need fr revisin f the guideline n clinical investigatin f medicinal prducts in the

More information

International Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant

International Experts Meeting on Severe Accident Management in the Light of the Accident at the Fukushima Daiichi Nuclear Power Plant IAEA-CN-233 Internatinal Experts Meeting n Severe Accident Management in the Light f the Accident at the Fukushima Daiichi Nuclear Pwer Plant Organized in cnnectin with the implementatin f the IAEA Actin

More information

Statement of Work for Linked Data Consulting Services

Statement of Work for Linked Data Consulting Services A. Backgrund Infrmatin Statement f Wrk fr Linked Data Cnsulting Services The Natinal Library f Medicine (NLM), in Bethesda, Maryland, is a part f the Natinal Institutes f Health, US Department f Health

More information

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013

A Unified Approach to Conflict Mineral Compliance for the Tungsten Industry. The Westin, Sydney, 23 September 2013 A Unified Apprach t Cnflict Mineral Cmpliance fr the Tungsten Industry The Westin, Sydney, 23 September 2013 Backgrund Cmpliance f public US dwnstream tungsten users with the reprting requirements f the

More information

Campus Climate Survey

Campus Climate Survey Campus Climate Survey Executive Summary www.ecu.edu/ecyu 2016 A prject spnsred by the Office fr Equity and Diversity Executive Summary Prject Backgrund In FY 2013-2014, the Campus Climate Cmmissin prpsed

More information

Introduction Teaching Interpretation

Introduction Teaching Interpretation Intrductin Teaching Interpretatin AUTHOR: Kyle Vanderwall Grandville High Schl, Grandville, MI Intrductin The AP U.S. Histry Curriculum Framewrk defines interpretatin in the fllwing way: Interpretatin

More information

Annual Assembly Abstract Review Process

Annual Assembly Abstract Review Process Annual Assembly Abstract Review Prcess AAHPM and HPNA cllabrate t review and select abstracts fr Annual Assembly. The cmmittees meet prir t the calls t review and update the Assembly bjectives (Planning

More information

1100 Marie Mount Hall College Park, Maryland Tel: (301) Fax: (301)

1100 Marie Mount Hall College Park, Maryland Tel: (301) Fax: (301) UNIVERSITY SENATE 1100 Marie Munt Hall Cllege Park, Maryland 20742-7541 Tel: (301) 405-5805 Fax: (301) 405-5749 http://www.senate.umd.edu March 31, 2017 Jrdan Gdman Chair, University Senate 2208G Physical

More information

True Patient & Partner Engagement How is it done? How can I do it?

True Patient & Partner Engagement How is it done? How can I do it? True Patient & Partner Engagement Hw is it dne? Hw can I d it? GROUP TECHNICAL ASSISTANCE JANUARY 18, 2017 COLORADO FOUNDATION FOR PUBLIC HEALTH AND THE ENVIRONMENT Webinar Objectives 1. Describe patient

More information

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder?

Q 5: Is relaxation training better (more effective than/as safe as) than treatment as usual in adults with depressive episode/disorder? updated 2012 Relaxatin training Q 5: Is relaxatin training better (mre effective than/as safe as) than treatment as usual in adults with depressive episde/disrder? Backgrund The number f general health

More information

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan

Bariatric Surgery FAQs for Employees in the GRMC Group Health Plan Bariatric Surgery FAQs fr Emplyees in the GRMC Grup Health Plan Gergia Regents Medical Center and Gergia Regents Medical Assciates emplyees and eligible dependents wh are in the GRMC Grup Health Plan (Select

More information

Human papillomavirus (HPV) refers to a group of more than 150 related viruses.

Human papillomavirus (HPV) refers to a group of more than 150 related viruses. HUMAN PAPILLOMAVIRUS This infrmatin may help answer sme f yur questins and help yu think f ther questins that yu may want t ask yur cancer care team; it is nt intended t replace advice r discussin between

More information

Cancer Association of South Africa (CANSA)

Cancer Association of South Africa (CANSA) Cancer Assciatin f Suth Africa (CANSA) Fact Sheet and Psitin Statement n Cannabis in Suth Africa Intrductin Cannabis is a drug that cmes frm Indian hemp plants such as Cannabis sativa and Cannabis indica.

More information

US Public Health Service Clinical Practice Guidelines for PrEP

US Public Health Service Clinical Practice Guidelines for PrEP Webcast 1.3 US Public Health Service Clinical Practice Guidelines fr PrEP P R E S ENTED BY: M A R K T H R U N, M D A S S O C I AT E P R O F E S S O R, U N I V E R S I T Y O F C O L O R A D O, D I V I S

More information

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018)

Breast Cancer Awareness Month 2018 Key Messages (as of June 6, 2018) Breast Cancer Awareness Mnth 2018 Key Messages (as f June 6, 2018) In this dcument there are tw sectins f messages in supprt f Cancer Care Ontari s Breast Cancer Awareness Mnth 2018: 1. Campaign key messages

More information

The Great Divide: Is it Operant or Classical? Lindsay Wood

The Great Divide: Is it Operant or Classical? Lindsay Wood The Great Divide: Is it Operant r Classical? Lindsay Wd Behavir cnsultants navigate multiple pathways in the curse f planning treatments. At the tp f ur list f cnsideratins is paradigm apprach: the chice

More information

Appendix C. Master of Public Health. Practicum Guidelines

Appendix C. Master of Public Health. Practicum Guidelines Appendix C Master f Public Health Practicum Guidelines 0 Gergia State University, Schl f Public Health Master f Public Health Practicum Guidelines Fr mre infrmatin, cntact Jessica Hwell Pratt, MPH Practicum

More information

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol.

A Phase I Study of CEP-701 in Patients with Refractory Neuroblastoma NANT (01-03) A New Approaches to Neuroblastoma Therapy (NANT) treatment protocol. SAMPLE INFORMED CONSENT A Phase I Study f CEP-701 in Patients with Refractry Neurblastma NANT (01-03) A New Appraches t Neurblastma Therapy (NANT) treatment prtcl. The wrd yu used thrughut this dcument

More information

World Confederation for Physical Therapy Congress , May Singapore

World Confederation for Physical Therapy Congress , May Singapore Wrld Cnfederatin fr Physical Therapy Cngress 2015 1-4, May Singapre Call fr applicatins fr Chair f the Internatinal Scientific Cmmittee The Executive Cmmittee f WCPT invites applicatins and suggestins

More information

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will:

Nutrition Care Process Model Tutorials. Nutrition Monitoring & Evaluation: Overview & Definition. By the end of this module, the participant will: Nutritin Care Prcess Mdel Tutrials Nutritin Care Prcess and Terminlgy Cmmittee Academy f Nutritin and Dietetics Nutritin Care Prcess Terminlgy 2015 Editin Nutritin Mnitring & Evaluatin: Overview & Definitin

More information

Call for evidence on the use of skin sensitisers, skin irritants and corrosive substances in textile and leather articles, hides and furs

Call for evidence on the use of skin sensitisers, skin irritants and corrosive substances in textile and leather articles, hides and furs Call fr evidence n the use f skin sensitisers, skin irritants and crrsive substances in textile and leather articles, hides and furs Backgrund dcument Backgrund Prductin and prcessing f textile and leather

More information

Improving Surveillance and Monitoring of Self-harm in Irish Prisons

Improving Surveillance and Monitoring of Self-harm in Irish Prisons HSE Mental Health Divisin Stewart s Hspital, Palmerstwn, Dublin 20 Tel: 01 6201670 Email: inf@nsp.ie www.nsp.ie Imprving Surveillance and Mnitring f Self-harm in Irish Prisns Prject Scpe Dcument 8 th June

More information

Catherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support

Catherine Worthingham Fellows of APTA Instructions for Writing a Letter of Support Catherine Wrthingham Fellws f APTA Instructins fr Writing a Letter f Supprt Fllwing is infrmatin designed t assist persns asked t write a letter f supprt fr a nminee fr the American Physical Therapy Assciatin

More information

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS

PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS PROCEDURAL SAFEGUARDS NOTICE PARENTAL RIGHTS FOR PRIVATE SCHOOL SPECIAL EDUCATION STUDENTS INTRODUCTION This ntice prvides an verview f the parental special educatin rights, smetimes called prcedural safeguards

More information

AUTHORISED BY: CEO. Introduction. Whistle Blowing

AUTHORISED BY: CEO. Introduction. Whistle Blowing GUIDELINE NAME: Field Cmplaints Disclsure Guidelines SECTION : Refer t Excel Guidelines list Dcument N: DISTRIBUTION: All Emplyees FIRST ISSUED: April 2013 DATE UPDATED: Dec 2014 ISSUED/UPDATED BY: Peple

More information

2017 Optum, Inc. All rights reserved BH1124_112017

2017 Optum, Inc. All rights reserved BH1124_112017 1) What are the benefits t clients f encuraging the use f MAT? Withut MAT, 90% f individuals with Opiid Use Disrder (OUD) will relapse within ne year. With MAT, the relapse rate fr thse with OUD decreases

More information

Related Policies None

Related Policies None Medical Plicy MP 3.01.501 Guidelines fr Cverage f Mental and Behaviral Health Services Last Review: 8/30/2017 Effective Date: 8/30/2017 Sectin: Mental Health End Date: 08/19/2018 Related Plicies Nne DISCLAIMER

More information

Catherine Worthingham Fellows of the APTA Instructions for Nominators

Catherine Worthingham Fellows of the APTA Instructions for Nominators Catherine Wrthingham Fellws f the APTA Instructins fr Nminatrs The fllwing infrmatin was prepared t aid nminatrs in making a nminatin fr the APTA membership categry f Catherine Wrthingham Fellw. Please

More information

Seeking and Appraising Evidence

Seeking and Appraising Evidence EWMA Educatinal Develpment Prgramme Curriculum Develpment Prject Educatin Mdule: Seeking and Appraising Evidence Latest review: August 2012 Educatin Mdule: Seeking and Appraising Evidence ABOUT THE EWMA

More information

Full-time or part-time to a minimum of 0.8FTE (30 hours per week) Job Reference: CLS00161

Full-time or part-time to a minimum of 0.8FTE (30 hours per week) Job Reference: CLS00161 Jb Title: Medical Statistician Grade: 8 Salary: 42,418 t 47,722 per annum Department: Research Design Service (RDS) and Leicester Clinical Trials Unit (LCTU) Cntract: Open ended cntract subject t fixed

More information

Completing the NPA online Patient Safety Incident Report form: 2016

Completing the NPA online Patient Safety Incident Report form: 2016 Cmpleting the NPA nline Patient Safety Incident Reprt frm: 2016 The infrmatin cntained within this dcument is in line with the current Data Prtectin Act (DPA) requirements. This infrmatin may be subject

More information

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018

Wound Care Equipment and Supply Benefits to Change for Texas Medicaid July 1, 2018 Wund Care Equipment and Supply Benefits t Change fr Texas Medicaid July 1, 2018 Infrmatin psted May 11, 2018 Nte: Texas Medicaid managed care rganizatins (MCOs) must prvide all medically necessary, Medicaid-cvered

More information

S.K.J Construction Ltd Groundwork & Civil Engineering

S.K.J Construction Ltd Groundwork & Civil Engineering S.K.J Cnstructin Ltd Grundwrk & Civil Engineering SUBSTANCE MISUSE POLICY 1 2 SUBSTANCE MISUSE POLICY 1 INTRODUCTION Plicy Aims Frm the viewpint f health and safety at wrk, SKJ Cnstructin Ltd (the Cmpany)

More information

General reviewer guidelines can be found here:

General reviewer guidelines can be found here: Guidelines fr reviewers Registered Reprts are a frm f empirical article in which the methds and prpsed analyses are pre-registered and reviewed prir t research being cnducted. This frmat f article seeks

More information

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher:

Year 10 Food Technology. Assessment Task 1: Foods for Special Needs. Name: Teacher: Year 10 Fd Technlgy Assessment Task 1: Fds fr Special Needs Name: Teacher: Due Date: Term 2, Week 1 Type f Task: Design Task Planning Fd Requirements Cllectin f Assessment: Submit in Class Assessment Plicy:

More information

UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES

UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES UNIT 6. DEVELOPING THREAT/HAZARD-SPECIFIC ANNEXES This page intentinally left blank. UNIT INTRODUCTION Visual 6.1 This unit presents infrmatin n annexes that shuld be included in a schl emergency peratins

More information

Vaccine Impact Modelling Consortium

Vaccine Impact Modelling Consortium Vaccine Impact Mdelling Cnsrtium Annual meeting 2017 - Summary meeting reprt Windsr, UK February 28 March 2, 2017 Objectives f the Vaccine Impact Mdelling Cnsrtium The Vaccine Impact Mdelling Cnsrtium

More information

FOUNDATIONS OF DECISION-MAKING...

FOUNDATIONS OF DECISION-MAKING... Table f Cntents FOUNDATIONS OF DECISION-MAKING... Errr! Bkmark nt Describe the decisin-making prcess pp.62-66... Errr! Bkmark nt Explain the three appraches managers can use t make decisins pp.67-70 Errr!

More information

A fake medicine that passes itself off as a real, authorised medicine. (1)

A fake medicine that passes itself off as a real, authorised medicine. (1) Falsified medicines Index 1 Intrductin 2 Types f falsified medicines 3 Eurpean regulatin n falsified medicines 4 Risks f falsified medicines 5 Buying medicine nline safely 6 References 7 Further resurces

More information

TERMS OF REFERENCE (ToR) NATIONAL INDIVIDUAL CONSULTANCY

TERMS OF REFERENCE (ToR) NATIONAL INDIVIDUAL CONSULTANCY TERMS OF REFERENCE (TR) NATIONAL INDIVIDUAL CONSULTANCY T Develping training materials fr a Human Develpment Mdule Applicatin Type: External vacancy Jb Title: Individual Cnsultancy (IC) Categry: Duty Statin:

More information

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by

The estimator, X, is unbiased and, if one assumes that the variance of X7 is constant from week to week, then the variance of X7 is given by ESTIMATION PROCEDURES USED TO PRODUCE WEEKLY FLU STATISTICS FROM THE HEALTH INTERVIEW SURVEY James T. Massey, Gail S. Pe, Walt R. Simmns Natinal Center fr Health Statistics. INTRODUCTION In April 97, the

More information

William Paterson University College of Science and Health DEPARTMENT OF PUBLIC HEALTH HealthyU Syllabus

William Paterson University College of Science and Health DEPARTMENT OF PUBLIC HEALTH HealthyU Syllabus William Patersn University Cllege f Science and Health DEPARTMENT OF PUBLIC HEALTH HealthyU Syllabus 1. Title & Number f Curse: PBHL 1100-81 HealthyU (3 Credits) 2. Department f Public Health: Department

More information

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics

Independent Charitable Patient Assistance Program (IPAP) Code of Ethics Independent Charitable Patient Assistance Prgram (IPAP) Cde f Ethics Independent charitable patient assistance prgrams (IPAPs) fcus n the needs f patients wh are insured, meet certain financial limitatin

More information

Individual Assessments for Couples Treatment with HFCA

Individual Assessments for Couples Treatment with HFCA Individual Assessments fr Cuples Treatment with HFCA Jennifer S. Ripley, Ph.D. Many appraches t cuples therapy include an individual assessment whenever a cuple cmes fr treatment. Therapists shuld be aware

More information

FDA Dietary Supplement cgmp

FDA Dietary Supplement cgmp FDA Dietary Supplement cgmp FEBRUARY 2009 OVERVIEW Summary The Fd and Drug Administratin (FDA) has issued a final rule regarding current gd manufacturing practices (cgmp) fr dietary supplements that establishes

More information

The data refer to persons aged between 15 and 54.

The data refer to persons aged between 15 and 54. Drug-related hspital stays in Australia 1993-2005 Prepared by Amanda Rxburgh and Luisa Degenhardt, Natinal Drug and Alchl Research Centre Funded by the Australian Gvernment Department f Health and Ageing

More information

NYS Common Core ELA & Literacy Curriculum Grade 12 Module 4 Unit 1 Lesson 14

NYS Common Core ELA & Literacy Curriculum Grade 12 Module 4 Unit 1 Lesson 14 12.4.1 Lessn 14 Intrductin In this final lessn f the unit, the 12.4.1 End-f-Unit Assessment, students craft a frmal, multi-paragraph respnse t ne f tw prmpts f their chice. Each f the tw ptins requires

More information

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009

CSHCN Services Program Benefits to Change for Outpatient Behavioral Health Services Information posted November 10, 2009 CSHCN Services Prgram Benefits t Change fr Outpatient Behaviral Health Services Infrmatin psted Nvember 10, 2009 Effective fr dates f service n r after January 1, 2010, benefit criteria fr utpatient behaviral

More information

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin

Service Change Process. Gateway 1 High-level Proposition. Innovation project name: Patient Self-Monitoring/Management of Warfarin Service Change Prcess Gateway 1 High-level Prpsitin Innvatin prject name: Patient Self-Mnitring/Management f Warfarin NHS Bury Please describe the service change being prpsed. Please describe what service(s)

More information

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator

Continuous Quality Improvement: Treatment Record Reviews. Third Thursday Provider Call (August 20, 2015) Wendy Bowlin, QM Administrator Cntinuus Quality Imprvement: Treatment Recrd Reviews Third Thursday Prvider Call (August 20, 2015) Wendy Bwlin, QM Administratr Gals f the Presentatin Review the findings f Treatment Recrd Review results

More information

Interpretation. Historical enquiry religious diversity

Interpretation. Historical enquiry religious diversity Name: Year 8 Histry Prject 3: D The Cmmnwealth Games Still Matter In The 21 st Century? Mdule: Date Set: Deadline: Descriptin f the task: The prject is split int three separate parts: The prject is split

More information

Social Learning Theories

Social Learning Theories Scial Learning Theries - Careful scientific prcedures and methdlgy that characterize the behaviurist apprach Albert Bandura - Brn in small twn Alberta - Plish decent - Only sn with 5 sisters - Interested

More information

Meeting the Nutritional Requirements of Individuals with Dementia

Meeting the Nutritional Requirements of Individuals with Dementia Unit 15: Understanding and Meeting the Nutritinal Requirements f Individuals with Dementia Unit reference number: D/616/7124 Level: 3 Unit type: Optinal Credit value: 3 Guided learning hurs: 26 Unit summary

More information

Section 5. Study Procedures

Section 5. Study Procedures Sectin 5. Study Prcedures 5.1 Visit Lcatins... 1 5.2 Eligibility Determinatin... 1 5.3 Screening Visit... 2 5.3.1 Screening and Enrllment Timeframe... 2 5.3.2 Screening Visit Prcedures... 2 5.3.3 Screening

More information

A. Catalonia World Health Organization Demonstration Project

A. Catalonia World Health Organization Demonstration Project A. Catalnia Wrld Health Organizatin Demnstratin Prject In 1989, the Health Department f Catalnia (Spain) and the Cancer Unit at the WHO (Geneva) designed and planned a demnstratin prject fr implementatin

More information

(Please text me on once you have submitted your request online and the cell number you used)

(Please text me on once you have submitted your request online and the cell number you used) Dear Thank yu fr yur email, nted. Belw steps n hw t register as a service prvider. Please nte that nce yu have requested t becme a service prvider, yu need t sms/what s up me n 0826392585, in rder t activate

More information

Annex III. Amendments to relevant sections of the Product Information

Annex III. Amendments to relevant sections of the Product Information Changes t the Prduct infrmatin as apprved by the CHMP n 13 Octber 2016, pending endrsement by the Eurpean Cmmissin Annex III Amendments t relevant sectins f the Prduct Infrmatin Nte: These amendments t

More information

A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation

A catalogue of criteria to objectify the harm-benefit analysis according to Austrian legislation LINZ 2013 18th Eurpean Cngress n Alternatives t Animal Testing EUSAAT 2013 15th Annual Cngress f EUSAAT 15 18 September 2013, University f Linz, Austria A catalgue f criteria t bjectify the harm-benefit

More information

CHS 283: Evidence-based Health Promotion for Older Adults

CHS 283: Evidence-based Health Promotion for Older Adults CHS 283 Winter 2015: Evidence-based Health Prmtin fr Older Adults Syllabus, page 1 CHS 283: Evidence-based Health Prmtin fr Older Adults Winter 2015 Thursdays 12-3pm Lcatin: CHS 41-235 Instructr: Janet

More information